

BMJ Open

A mixed-methods study of a large-scale programme to improve patient safety using a harm-free care approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011886
Article Type:	Research
Date Submitted by the Author:	11-Mar-2016
Complete List of Authors:	Power, Maxine; Salford Royal NHS Foundation Trust, HAELO Brewster, Elizabeth; University of Lancaster, Medical Education Parry, Gareth; Harvard Medical School, Brotherton, Ailsa; Salford Royal NHS Foundation Trust, HAELO Minion, Joel; University of Bristol, Social Medicine Ozieranski, Piotr; University of Bath McNicol, Sarah; Manchester Metropolitan University Department of Exercise and Sport Science Harrison, Abigail; Salford Royal NHS Foundation Trust, Haelo DixonWoods, Mary; University of Leicester, Health Sciences
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health policy
Keywords:	patient safety, measurement, improvement programmes, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, quality improvement collaboratives, mixed-methods

SCHOLARONE™
Manuscripts

only

A mixed-methods study of a large-scale programme to improve patient safety using a harm-free care approach

AUTHORS

Maxine Power¹

Liz Brewster²

Gareth Parry³

Ailsa Brotherton¹

Joel Minion⁴

Piotr Ozieranski⁵

Sarah McNicol⁶

Abigail Harrison¹

Mary Dixon-Woods^{7*}

¹Haelo, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK

²Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YW, UK

³Institute for Healthcare Improvement, 20 University Rd, Cambridge, MA 02138, United States

⁴Data to Knowledge Group, School of Social and Community Medicine, University of Bristol, Bristol BS8 2BN, UK

⁵Department of Social and Policy Sciences, University of Bath, Bath, BA2 7AY, UK

⁶Education and Social Research Institute, Manchester Metropolitan University, Crewe Green Road, Crewe, Cheshire, CW1 5DU

⁷SAPPHIRE Group, Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK

*Corresponding author. *Professor of Medical Sociology and Wellcome Trust Investigator*, Department of Health Sciences, College of Medicine, Biological Sciences and Psychology, University of Leicester, Centre for Medicine, University Road, Leicester, LE1 7RH, UK. Tel: + 44 116 2297262 email: md11@le.ac.uk

Keywords: Quality improvement collaboratives; Quality Improvement, Implementation, Patient Safety, National Health Service

Abstract

Objectives: A large-scale two-phase quality improvement programme aimed to: 1) develop a shared national, regional and locally aligned safety focus for four high-cost, high volume harms; 2) establish a new measurement system based on a composite measure of “harm-free” care; 3) deliver improved outcomes. We aimed evaluate whether the programme achieved its aims and to characterise the influences on achievement.

Setting: Services for National Health Service (NHS) patients in England.

Participants: NHS staff.

Interventions: Phase 1 involved a quality improvement collaborative intended to involve 100 organisations; phase 2 used financial incentives for data collection.

Measures: Mixed-method study involving quantitative and qualitative assessment, including, for Phase 1, analysis of regional plans, rates of data submission and clinical outcomes and a process evaluation. Only data on submission rates and clinical outcomes were available for Phase 2.

Results: A context of extreme policy-related structural turbulence impacted strongly on Phase 1. Most regions’ plans did not demonstrate full alignment with the national programme. Only two were able to recruit the target of 10 organisations for the collaborative. Attrition in numbers of staff attending the collaborative meetings occurred over time. Though collaborative participants saw the principles underlying the programme as attractive, useful and innovative, they often struggled to convert enthusiasm into change. Developing the measurement system was arduous, yet continued to be met by controversy. Data submission rates remained patchy throughout Phase 1 but improved in reach and consistency in Phase 2 in response to financial incentives. Some evidence of improvement in clinical outcomes over time could be detected but was hard to interpret owing to variability in the denominators.

Conclusions: These findings offer important lessons for large-scale improvement programmes, particularly when they seek to develop novel concepts and measures. External contexts may exert far-reaching influence. The challenges of developing measurement systems not be underestimated.

Strengths

- The mixed-methods design used by this study enabled assessment both of extent to which a large-scale improvement programme met its aims and of influences on achievement.
- The study reveals the impact of policy and structural turbulence on ability to achieve change in health systems.
- The importance of a rigorous development phase for improvement programmes, including significant investment upfront in measurement and data systems, was identified.

Weaknesses

- The process evaluation of the first phase of the programme may have been biased towards those with more positive views.
- The absence of a process evaluation for the second phase of the programme is a further limitation.

Introduction

How best to ensure the safety of patients continues to challenge health systems worldwide. [1-3] Recent years have seen multiple efforts to secure improvements. Some have multiple safety targets and seek generalised strengthening of organisational systems, processes and cultures, [4] [5, 6] while others target specific areas of harm or practice. [7] [8] [9] Whatever their form, improvement programmes typically measure outcomes one by one, with incidence for each – for example central venous catheter bloodstream infections or unplanned readmissions to hospital - reported singly and separately, rather than in terms of how many harms each person suffered. Most also focus on specific, well-bounded healthcare settings and measure harms that are assumed to be attributable to the care provided in those environments.

Some (though not all) patient safety programmes have reported welcome successes in relation to specific harms. From the patient’s perspective, however, a focus on single outcomes in well-bounded healthcare settings may be deficient, potentially obscuring individuals’ experiences across pathways of care and their exposure to concatenations of multiple adverse events. [10] Addressing harms singly also has other unintended consequences, including the reinforcement of disciplinary boundaries. Infection control nurses may, for example, work in isolation from tissue viability nurses with the same patients. Thus, a potentially more useful approach to safety might focus on the extent to which patients escape all possible harms and could thus be deemed to have experienced care that is “harm-free”. Yet how to secure improvement in harm-free care is not clear.

The available evidence suggests that large-scale programmes may offer some important advantages over single-organisation efforts [11] by supporting the infrastructure for improvement, including the development of well-founded interventions and data systems [12] as well as activating the social conditions, peer-norming effects and shared learning most likely to foster change [13-15] and enabling change at scale. A growing body of evidence now points to the features essential to the success of such programmes, including shared goals among participants, clinician engagement, clinical champions, and the importance of well-designed, theoretically sound interventions [5, 16-18]. However, large-scale improvement programmes continue to show a mixed picture of success, [5, 19] suggesting that much remains to be learned, particularly when novel interventions or measures are used. In this article, we report a study of a large-scale programme seeking to promote an innovative approach to harm-free care in England.

The programme had three major goals:

- Develop a shared national, regional and locally aligned safety focus for four high-cost, high volume harms (venous thrombo-embolism (VTE), pressure ulcers, urinary tract infection in

patients with urinary catheters, and falls). These four harms were selected because they account for a large proportion of all avoidable injury to patients and share many underlying factors (e.g. mobility, medication management, nutrition, hydration) relating to basic patient care, yet may involve trade-offs in managing risk; [1, 20]

- Establish a measurement system based on the principle that a new patient-centred measure that would “bundle” harms into a single, composite score of harm-free care would bring new insights into harm rates, enable clinical teams to identify and recognise where problems lay, and motivate local improvement;
- Deliver improved clinical outcomes, with a specific objective of ensuring that 95% of patients would be harm-free.

Run as part of the Department of Health’s Quality, Innovation, Productivity and Prevention (QIPP) ‘Safe Care’ workstream,[21] the programme was led by a dedicated national programme team. The programme did not seek to develop new technical interventions for managing the four harms nor to set targets, but instead sought to: ensure that addressing the four harms together for each patient was identified as a priority for organisations, support organisations and teams in implementing existing good practice in relation to the four harms, and provide a well-founded means of surveillance, monitoring and feedback on harm-free care.

It ran in two distinct phases. The first phase ran September 2010 to April 2012, including a three-month preparatory period at the beginning (September 2010-December 2010) and a six-month maintenance period at the end (October 2011-April 2012). This first phase sought to pilot an approach to measuring and improving patient safety, to support a cohort of organisations to implement and test it, and ultimately to prepare the way for the subsequent use of the approach across all care settings in England. To achieve these aspirations, the national team undertook an intensive period of programme design, refinement of operational definitions, cycles of testing and learning, and developing and modifying a data collection tool for harm-free care.

This tool, which came to be known as the NHS Safety Thermometer, sought to enable collection of data that would both be comparable at a national level and useful in local improvement work, [22] and that would balance accurate measurement and standardised definitions with straightforward data collection methods that did not burden staff. The design period was followed by work to implement the programme through regional and local partnerships (Table 1), much of it organised through a voluntary quality improvement collaborative known as Safety Express.

Use of the collaborative model [23] was based on the theory that it would facilitate rapid shared learning and the mobilisation of collective cross-multidisciplinary action. [13] Consistent with the

1
2
3 BreakThrough Series collaborative approach, [24] Safety Express involved three learning events
4 where participants across the regions came together and action periods during which participants were
5 asked to implement improvement activities (e.g. setting up data collection systems and implementing
6 Plan-Do-Study-Act cycles). Participants were recruited through the 10 Strategic Health Authority
7 (SHA) regions then extant in the English NHS. Each region was asked to engage 10 participating
8 organisations serving a local population, and each of these organisations was asked to ensure that 10
9 staff members (primarily front-line clinicians) attended the learning events and that they tested the
10 NHS Safety Thermometer in a relevant caseload. The work of clinical teams in undertaking these
11 activities was supported by the regional and national teams, as well as by online resources and
12 detailed guidance on good practice interventions and on how to submit and interpret local data.
13 Participating organisations were asked to collect data on four wards (acute) or on their caseloads (non-
14 acute) on one day per month using the NHS Safety Thermometer and to submit it to a central data
15 collection facility. A six-month maintenance period during which organisations were asked to
16 continue submitting data followed the completion of Safety Express in September 2011. Some
17 support, albeit limited, was available to organisations on request during the maintenance period.

18
19
20
21
22
23
24
25
26
27 The second phase of the programme ran April 2012 to March 2013, when it expanded beyond the
28 original participants to include all settings providing care for NHS patients in England. An important
29 characteristic of this phase is that financial incentives were offered to all NHS organisations in
30 England to submit data on 100% of patients on one day per month using the NHS Safety
31 Thermometer. Only limited improvement support was available: the collaborative did not continue,
32 though access to online resources remained, and some limited support was available from the NHS
33 Institute for Improvement and Innovation up to March 2013. Some locally organised (not nationally
34 coordinated) support activity also took place.

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Our study aimed to assess how far the programme met its three aims and to identify and characterise
the influences on the achievement of these aims.

Methods

We used a mixed-method approach. During Phase 1 of the programme, quantitative data were
collected on the extent to which regional strategy was aligned to national goals, the number of
organisations that were submitting data on the four harms, and clinical outcomes. As part of a wider
study of quality and safety in the NHS, [25] a process evaluation of Safety Express was also
conducted, using interview, observational, questionnaire and documentary data. Approval for the
process evaluation was obtained from an NHS REC. Signed consent was obtained for interviews.

For reasons of resource, only quantitative data on submission rates and clinical outcomes were
available for Phase 2. Data on clinical outcomes were submitted by all participating organisations.

However, these organisations changed over time (especially between Phase 1 and Phase 2), leading to unstable denominators that increased in size and diversity over time. In order to identify whether collaborative participation had an effect and the shifting denominator, we undertook a subgroup analysis of the 12 organisations participating in the Safety Express collaborative from the outset who submitted data consistently.

All quantitative data were collected and analysed by the programme team; all qualitative data were collected and analysed by an evaluation team independent of programme team (Boxes 1 and 2).

Box 1: Quantitative data

Goal	Data	Analysis
Delivery of required programme outputs: inclusion of the four harms in each region's system-level strategy plans and QIPP improvement programmes.	Each region's progress extracted from plans and mapped on four occasions using a categorical rating scale.	A judgment was made by the programme team to determine whether the region was achieving four or more of the milestones (green), two to three (amber) or one or less (red).
Team engagement: participation in the collaborative, delivery of the required programme outputs and NHS Safety Thermometer data collection	The number of participating organisations and the number of attendees each region sent to each learning session in Safety Express was recorded.	Count data displayed as descriptive statistics and percentages.
Harm-free care clinical outcomes: absence of all four harms at the individual patient level	For each patient, data were collected by local clinicians on four outcomes (pressure ulcers, falls, urinary tract infection in patients with urinary catheters, and VTE) and submitted using the NHS Safety Thermometer. To allow for variation in organisations submitting data over time, two cohorts were formed: 1) Data from acute patients from the initial, Phase 1 Safety Express organisations consistently submitting between January 2011 and March 2013 2) Data from acute patients from all organisations submitting at any time between January 2011 and March 2013.	The composite measure of harm-free care was plotted over time using a control chart. To take account of over-dispersion, due to the large sample size, a P' control chart was used. Standard control chart rules were applied to indicate special and common cause variation and when a shift in the average occurred. Statistical analysis was performed using R-2.15.1 for Windows (http://cran.r-project.org/bin/windows/base/old/2.15.1/).

Box 2: Process Evaluation (Phase 1 only)

Method	Data	Analysis
Semi-structured interviews. A prompt guide was used to elicit experiences and views of the programme from purposively sampled stakeholders. Interviews were audio-recorded and transcribed.	Interviews with seven QIPP national team members, six local coordination leads and 11 programme participants. The local programme co-ordination leads were more senior nursing staff, located in four of the 10 Strategic Health Authorities. The programme participants interviewed were mainly nursing staff with responsibility for clinical governance, tissue viability, or patient safety and were based in eight of the 10 regions.	Analysis was based on the constant comparative method, facilitated by NVivo software [26, 27]. Open codes were generated through close reading of transcriptions. Reflection and interpretation was used to produce a higher level of abstraction and thematic categories. Coding of transcripts was supported by NVIVO 8 software.
Observations. Observers took detailed field notes and held debrief sessions, which were audio-recorded and transcribed.	Ethnographic observations to assess the experience of participating in the programme were conducted at Six Safety Express learning events.	As above
Survey. Based on the observational and interview data, an online survey was developed and circulated to all learning event participants. Covering implementation of the programme, data measurement and organisational involvement, the majority of the 40 survey questions were multiple-choice or Likert scale, with four free-text questions used to elicit more in-depth responses.	The survey received 157 anonymised responses; because of the method of email distribution, it was not possible to calculate a response rate. A diverse selection of respondents completed the survey (Table 2), reflecting those participating in the project.	Descriptive analyses of the survey data, with free-text responses coded using content analysis. [28]
Documents. Project documentation and key policy documents were purposively sampled.	~20 relevant documents were collected from the programme team and from QIPP and other websites.	Review and summary.

Results

Data on clinical outcomes submitted were available over both phases on the programme, though the composition of the contributing organisations and the consistency with which individual organisations submitted data varied over time (Figs 1a and 1b). The process evaluation, which focused on Phase 1, involved 24 interviews, 157 survey responses, 48 hours of observation, and around 20 documents. Quotations are numbered to indicate different participants and preserve anonymity.

Aim 1: Develop a shared national, regional and locally aligned safety focus for the four harms

Evidence on the development of a shared national, regional and locally aligned safety focus for the four harms during Phase 1 was assessed. A mixed picture emerged. Substantial variability (Table 1) was evident in how far the regions' plans were aligned with those of the national programme. Only two of the ten regions' plans were rated as 'green' on the rating scale by September 2011 (almost nine months after the start of the programme) and only one organisation maintained this for over a year (Table 3).

All 10 regions signed up to participate in the Safety Express collaborative, but only two were able to reach the goal they were set of recruiting 10 participating organisations (range 5-31). None was able to provide 100 participants at each learning event (range 22-118), meaning that the goal of enrolling 1000 front-line clinicians was not reached. In seven regions, attrition occurred in the number of delegates attending the learning events as the programme progressed.

Interviews showed that many (though not all) participants saw the principles underlying the programme as attractive, useful and innovative. Much support was expressed for the programme principle of taking a holistic approach to harm: almost two-thirds (64%) of survey participants strongly agreed or agreed that the four harms chosen were the most important for their organisation to address, and interview participants were also generally positive about the approach to harm-free care. Survey and interview data suggested that participants generally valued the collaborative features of the programme, with the learning sessions and encouragement from the national team seen as particularly useful. Observations at the Safety Express learning sessions found that participants demonstrated considerable enthusiasm, and that the sessions helped to build relationships and share learning, ideas and practical tools.

I mean we could bounce ideas off them, say we have thought about this, is anybody else doing something similar who we can talk to? So they have got that information to signpost us. (Learning session participant I-05)

However, the ambition of the programme daunted some participants. Just under half (44.6%) of survey respondents reported that the programme was greeted with 'initiative fatigue' in their organisation. Though nearly three-quarters (73.2%) reported that achieving 'harm-free' care was a realistic goal for the NHS, just over a third (34.8%) thought their organisation was close to attaining it. Translating the enthusiasm generated by collaborative activities into local action remained a challenge for many.

The ethos of it is obviously just what it should be, but how achievable it is I am not sure. (Learning session participant I-06)

1
2
3 *Brilliant for networking and we all left feeling positive [...] it was the sustainability following*
4 *the events [that was] difficult. Because obviously you leave the room full of ideas and you go*
5 *back to your everyday work and... it's very difficult to keep it going, I have to say. (Learning*
6 *session participant)*
7

8
9 The most profound influence on the ability of regions and organisations to engage with the
10 programme appeared to be the context of extreme policy turbulence and structural change. Analysis of
11 the 2009-12 policy context (Fig. 2) identified the transformations of the NHS architecture associated
12 with the Health and Social Care Act (2012), with the effects evident both before (in anticipation of)
13 and after the passing of the legislation. Alongside many changes, a new national commissioning board
14 was created (NHS England) and the 10 Strategic Health Authorities were replaced by four regional
15 offices of NHS England. The national bodies that had supported system change were decommissioned
16 (the NHS Institute in March 2013 and the National Patient Safety Agency in June 2012). Loss of
17 senior leadership at the national and regional level contributed to voids of coordination and
18 communication during the programme. In all but one region, the problems faced in delivering the
19 programme caused by external and internal turbulence necessitated implementation of a recovery plan
20 and the establishment of direct communication between the national team and the participating teams
21 rather than through the regions.
22
23
24
25
26
27
28

29 **Aim 2: Establish a measurement system to understand the burden of the four harms**

30
31 The programme largely succeeded in its aim of establishing a measurement system, but the process of
32 its development was effortful and it continued to generate considerable controversy throughout the
33 programme.
34
35
36

37 A prototype of the NHS Safety Thermometer data collection tool was developed by the national
38 programme team during the design period of Phase 1, and refined iteratively thereafter. Intended to be
39 used by frontline staff, who were asked to collect data on the four harms by reviewing patients'
40 records and examining and speaking to the patient harms, [29]the tool enabled entry of data through
41 an online spreadsheet. It provided instant data display for the participating clinical teams, and, through
42 a merge function, supported aggregation to give whole organisational, regional and national datasets.
43 Though rates of each of the four harms could be viewed separately, a novel feature of the NHS Safety
44 Thermometer was its ability to generate a composite measure of "harm-free" care to indicate the
45 proportion of patients who had not experienced any of the four harms.
46
47
48
49
50
51

52 During Safety Express, the 10 regions were asked to coordinate collection of data using the NHS
53 Safety Thermometer from ten organisations from their region. Each of these 10 organisations was
54 asked to collect data and submit on four wards (acute) or caseloads (non-acute) on one day per month.
55 In interviews, many Safety Express participants saw the NHS Safety Thermometer as innovative,
56
57
58
59
60

1
2
3 providing a useful and valuable dataset that could be used to drive improvements and provide
4 evidence of progress. They reported that the tool had several advantages in comparison with some
5 available methods of measurement, including the potential that the tool provided for intervening and
6 improving care on the spot. Some participants reported that working across all four harms helped to
7 avoid duplication, both of data collection and effort.
8
9

10
11 *The sheer number of nurses that have said: what is fabulous about it is that it means that I*
12 *can improve patient care while the patient is right here, still in the bed and still when I can do*
13 *something about it [...] When I did the Safety Thermometer it was clear the [patient] had not*
14 *had a VTE assessment done so I got the junior doctor to do it for them. (National team*
15 *member I-22)*
16
17

18
19 *My understanding was that [the harms] selected themselves really because they were the*
20 *biggest category of avoidable harms in healthcare and from that point of view I think they*
21 *were the right ones to focus on. (Local organiser I-05)*
22

23 Some participants (including around 20% of survey respondents) commented on the value of having
24 shared definitions and being able to collect comparable data on harms across organisations.
25

26
27 *The consistent approach across the country so we measure apples and apples. [Survey]*
28

29 *[NHS Safety Thermometer] is the first time that we have actually been nationally able to*
30 *measure something in the same way to the same definition... I don't think that has happened*
31 *in anywhere in Europe. (Local organiser I-15)*
32

33 However, developing and deploying the NHS Safety Thermometer was not without substantial
34 challenges. The time required to develop the tool was lengthy, much greater than the programme team
35 had initially anticipated; modifications were still being made to the data collection instrument late in
36 2011, almost eleven months after the start of the collaborative. Questions and disagreement about the
37 inclusion of the harms and their exact definition dogged the development of the programme, in
38 particular by introducing delays while consensus was sought. This was particularly true of the
39 inclusion of the measure relating to urinary tract infection in patients with urinary catheters, which
40 some participants disputed or reported was unclear. Over one in 10 (11.8%) of survey respondents felt
41 that the inclusion of this measure in the programme was not soundly based in scientific evidence,
42 compared with just 2% feeling that there was no scientific basis to include VTE.
43
44
45
46
47
48

49 *I think the other thing with falls and pressure ulcers is that there are quite clear definitions*
50 *that everyone agrees on. For catheter associated UTIs it has not been the same... That has*
51 *created quite a lot of confusion. [Local organiser I-15]*
52
53
54
55
56
57
58
59
60

1
2
3 *Because of some of the questions around the measurement piece, because of the questions*
4 *around – well what does the definition for UTI look like in my organisation compared to*
5 *yours? Very valid conversations but nonetheless quite stalling [National team member I-18]*
6

7
8 Some participants expressed a very strong view that a national measurement strategy was neither
9 useful nor appropriate. Organisations and individuals were often already using their own local
10 definitions of some or all of the four harms, and had established methods of data collection and data
11 display. Participants did not always demonstrate consensus that the four harms chosen by the
12 programme were the most important focus for improvement efforts in their own organisations.
13
14

15
16 *The difficulty with it is that if we've already got a system and a process in place in some*
17 *organisations to measure what they're doing against falls, pressure ulcers, whatever,*
18 *individually, the link hasn't been there. (Local organiser I-24)*
19

20
21 The number of updates to the tool over the course of Safety Express in response to feedback caused
22 some frustration among participants, who did not always appreciate the developmental nature of the
23 first phase of the programme. Participants also complained that the tool was not as easy to use as
24 intended. The extent to which data collection would need to be supported was initially under-
25 estimated by the national team; some months in, it became clear that there was a skills gap in relation
26 to measurement in many participants, who were often inexperienced in collecting or using data for
27 improvement. The team produced a suite of materials to support learning and implementation and
28 delivered a series of learning workshops across the country on measuring improvement, including
29 technical capability (actual use of the data tool). In the survey, half (50.0%) of respondents described
30 the tool as 'straightforward,' but nearly half (44.3%) felt that data collection was a major burden.
31 Some teams struggled to integrate the new data collection into their existing practice.
32
33
34
35
36

37
38 *It's time-consuming. It's another thing that a clinician has to do. (Learning session participant*
39 *I-01)*
40

41
42 Around a third (32.6%) of survey respondents questioned the reliability of the data collected,
43 indicating that they believed that it was 'vulnerable to "gaming" by organisations trying to look
44 good' and that the data was not comparable across organisations. One problem was that the NHS
45 Safety Thermometer asked data collectors to record whether the harm was 'old' or 'new' depending
46 on when it occurred. Staff reported that this was a problem because of the way the tool seemed to
47 obscure where and how the harm had occurred and opened up the possibility of blame.
48
49
50

51
52 *But because it went down on our record, it looked as though it was ours even though it goes*
53 *down as an old or a new, when you put those together it looks as though – oh look, they have*
54 *got pressure ulcers. (Learning session participant I-06)*
55

56
57 Substantial variability was evident in the extent to which organisations used the NHS Safety
58 Thermometer during Safety Express (Figs 1a and 1b). One region did not submit any data. In the first
59
60

1
2
3 month, only 12 acute organisations submitted data, making 712 patient-level entries. Rates of
4 organisational participation and data submission increased thereafter, with 140 organisations
5 submitting data at least once and an average of 60 organisations contributing data every month
6 throughout the collaborative. A total of 52,309 patient-level line entries were made during Safety
7 Express. A majority (71%) of monthly submissions contained at least 30 patients and 84% achieved at
8 least 20 patients. Data from hospital settings accounted for 90% of all data submitted, with the
9 remainder from non-acute settings including 3% from the patients' own home, 2% from nursing
10 homes and 5% from other settings. Within hospitals, 50% of the settings chosen by participants for
11 testing in hospitals were medical wards.

12
13
14
15
16
17 During the second, incentivised data collection phase of the programme, the number of organisations
18 contributing data increased dramatically: 719 organisations used the NHS Safety Thermometer during
19 2012/13 (146 acute, 573 non-acute). This resulted in a large increase in patient entries into the dataset:
20 1,882,558 patient entries (Fig. 1b). Diversity in the kinds of organisations contributing data also
21 increased during 2012-13, with particular growth in the proportion of patients from non-acute settings.
22 Of the non-acute, 136 were independent provider sites and 217 were nursing homes. During this
23 period, 58.3% of data were submitted from hospital settings, 7.8% from the patients' own home, 2.3%
24 from nursing homes and 31.6% from other settings.

30 31 **Aim 3: Deliver improved outcomes**

32 The extent to which the programme met its aim of delivering improved outcomes was difficult to
33 assess, given variability in the number and consistency of organisations submitting data over time.
34 Control chart rules were used to interpret data on harm-free care over the two phases of the
35 programme both in the specific initial Safety Express subgroup of 12 organisations who were the first
36 to join (Fig 3a) and, separately, all organisations (including the initial Safety Express subgroup)(Fig
37 3b).

38
39
40
41
42 The initial Safety Express subgroup organisations all reported data consistently over time. The
43 proportion of harm-free care reported by these organisations rose from 85.1% in January 2011 to
44 89.7% in April 2011 during Safety Express. This increased further to 91.4% by March 2012, and
45 remained stable up to March 2013 (throughout the incentivised data collection phase). (Fig 3a). The
46 proportion of patients who were deemed 'harm-free' in this subgroup did not reach the goal of 95%.

47
48
49
50
51 In all submitting trusts (including the initial Safety Express subgroup), the proportion of acute patients
52 reported as receiving harm-free care rose from 86.5% January 2011 to 90.2% by July 2011 during
53 Safety Express. This increased further to 92.2% in July 2012, and stabilized thereafter, during the
54 incentivised data collection phase (end of March 2013) (Fig. 3b). Again, the 95% aspirational goal
55 was not achieved.
56
57
58
59
60

Discussion

This mixed-method study of a large-scale, two-phase improvement programme using an innovative approach to harm-free care adds to the growing body of evidence on large-scale programmes as a means of securing change in healthcare. First, it illustrates the importance of significant upfront investment when launching new data collection tools based on novel concepts, especially when such tools seek to standardise the measures used across diverse settings. Second, it suggests that engagement in voluntary efforts such as quality improvement collaboratives may be contingent on relatively stable organisational and broader institutional contexts: participation and engagement in Safety Express remained patchy throughout its history. It was not until broader structures had settled, and a financial incentive for data collection was introduced in the second phase of the programme, that the reach and consistency of data submission improved. Third, this study illustrates the challenges in interpreting evidence relating to large-scale improvement. There is some indication that the proportion of patients experiencing harm-free care increased over the both phases of the programme, but trends over time in the aggregate submissions must be interpreted cautiously since the same organisations did not submit consistently over time nor did those who were submitting do so consistently, and case-mix varied over time.

One potentially tempting conclusion from this study is that the first phase of the programme was unnecessary since improved consistency of data submission did not occur until the second phase, which financially incentivised data collection. This second phase also saw possible improvements in clinical outcomes, even though little improvement support was available. Such a conclusion might suggest that future efforts to secure improvement should focus primarily on financial incentives, bypassing the messier and more uncertain path of voluntary, collaborative cooperation. But such an argument neglects the important developmental role played by the first phase. Without this, the second phase is likely to have foundered.

The developmental role of the first phase was especially critical in developing the NHS Safety Thermometer. Though quality improvement projects are known to be prone to measurement and data collection problems of various kinds, [30-32] the challenges in developing measures and securing legitimacy are seldom reported. The concepts behind the NHS Safety Thermometer were novel, emphasising a patient-centered approach that required rethinking of traditional metrics and methods of data collection and display. Significant technical and social innovation was required to maximise the chance that the data would be regarded as credible while minimising the risk that data would be too irksome or burdensome to collect. [33] Despite the level of investment and testing, some concerns

1
2
3 about consistency, relevance and fairness endured among those submitting data, as has been found
4 elsewhere.[34]
5
6

7 The first phase of the programme may have been important in developing approaches, definitions and
8 tools, but less clear was the success of the collaborative model in securing change. Though the harm-
9 free care concept was broadly recognised by Safety Express participants as an original and ingenious
10 way to think about patient safety, none of the regions met the engagement metrics; ability to engage
11 was adversely affected by massive system instability that contributed to distraction, diminished
12 energy, and voids of leadership. [35] It is also likely that the number of participants was too low to
13 achieve the necessary momentum in an area the size of England. Further complicating engagement
14 was the variation that existed between regions and between organisations in their approach to
15 implementation. Better understanding of such variation might have enabled the national programme
16 team to undertake a baseline assessment and co-design a bespoke programme with each locality.
17 These findings affirm earlier evidence [23] [30] [36] indicating that quality improvement
18 collaboratives may have some distinctive strengths but are far from a straightforward solution. It adds
19 to this evidence in demonstrating that the potential of collaboratives may be heavily contingent on
20 their political, economic and social contexts. Simply put, though they may have advantages over more
21 coercive methods for making change,[37] their success is likely to depend on a supportive outer
22 context. Better understanding of how and when collaboratives are the right approach is an especially
23 important goal given the known risks and limitations associated other means of achieving change,
24 including those associated with use of financial incentives.[38]
25
26
27
28
29
30
31
32
33
34

35 A limitation of our study is that it was not possible to conduct a process evaluation of the incentivised
36 data collection phase. This means that it is not easy to identify the mechanisms that might have
37 contributed to the possible improvements in proportion of harm-free care that appear to have
38 coincided with the introduction of the data collection requirement. One possibility is that the observed
39 improvement is simply an artefact of the data collection process; as data collection expanded, the
40 case-mix became more diverse and included a higher proportion of patients at lower risk of the four
41 harms. Another possibility is that the observed change was real: that clinical teams did use the NHS
42 Safety Thermometer as intended, recognising the value of a harm-free approach and using the data
43 displays to identify where practice was falling short and making changes. Such an interpretation is
44 consistent with the general observation that data plus feedback can act as an intervention, revealing
45 unwarranted variations in practices, processes and outcomes and helping to inform targets for
46 improvement [39] [40] A further possibility is that, perhaps anticipating financial incentives becoming
47 attached to performance on harm-free care (and not just the data collection), organisations found ways
48 of showing that they were “compliant”.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Other limitations of this study include possible bias of the sample interviewed in the process
4 evaluation towards those with more positive views, since those participating in the collaborative were,
5 almost by definition, more engaged. The online survey did provide another opportunity to contribute,
6 but it was still vulnerable to capturing the views of the more engaged. It is not clear how generalizable
7 the findings will be to other contexts.
8
9

10
11 These findings offer important lessons for large-scale improvement programmes. They show that the
12 effort and time required to reach and implement an agreed approach to measurement for
13 improvement, particularly when the measures are novel, should not be underestimated. Development
14 of measurement systems requires both cultural change and technical leadership. It is likely that at least
15 six months is needed before an improvement programme starts to allow systems to be optimised.
16 Even then, contestation about data definitions and complaints about data collection burden may
17 persist and should be anticipated. The collaborative model may have rich potential as a design and
18 developmental phase in large-scale improvement programmes, but may not on its own produce
19 change when external contexts are unfavourable.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests:

MP, AH and AB were seconded to the Department of Health QIPP programme which ran the projects described in this manuscript. No other authors have a competing interest.

Funding:

The Department of Health Policy Research Programme (Reference No 0770017) funded the research programme of which this evaluation was a part. Analysis of data and write-up of this paper was supported by a Wellcome Trust Senior Investigator award (MDW) WT097899

Ethics committee approval:

NHS Research Ethics Committee approval was obtained for the process evaluation from the Leicestershire, Northamptonshire & Rutland Research Ethics Committee 1 (reference: 10/H0406/38). All personal identifiers have been removed.

Contributorship:

MDW and MP were involved in the study concept and design. SM, JM and PO collected and analysed the qualitative data. GJP, AH and MP analysed the quantitative data. MP, LB, GJP, AB and MDW were involved in the drafting and revised the manuscript. All the authors were involved in the critical revision of the final version of the manuscript.

Acknowledgements:

We thank all of the many organisations and individuals who participated in this research programme for their generosity and support, and our collaborators and the advisory group for the programme. Thanks to Dr Kevin Stewart, (Royal College of Physicians Clinical Effectiveness Unit, London UK) for his clinical leadership throughout the Safety Express programme and Kate Cheema at the South East Coast Quality Observatory for support with design of the NHS Safety thermometer, data collection and analysis. We thank Kasia Noone and Matt Cope for coordinating production of the manuscript.

Data Sharing:

Additional unpublished data are not available.

Baseline assessment	Review 1	Review 2	Review 3	Final review
Safety Express Phase Reviews			Maintenance Phase Review	Incentivized Phase Review
Sept – Dec 2010	April 2011	Sept 2011	Sept 2012	March 2013
<ol style="list-style-type: none"> 1. A named individual in each region to link into the national team, appoint a local team and link into the QIPP team. 2. Identify areas of alignment and discourse between local, regional and national QIPP plans. 3. Recruit ten host organisations and ensure team composition included locality partners. 4. Identify regional faculty for a Safety Express improvement collaborative. 5. Field 100 people at learning session 1 of the collaborative. 	<ol style="list-style-type: none"> 1. Integration of the safe care plans into the regional QIPP plan. 2. Ten teams of ten participating in the collaborative. 3. Participation in fortnightly WebEx meetings (regional leaders) 4. Submission of monthly data using the NHS Safety Thermometer 5. Faculty support, (both ‘national’ and ‘regional’ – national included subject matter experts, i.e. in tissue viability / pressure ulcers and nutrition. Regional – leading clinicians and Q.I. experts) to teams between learning sessions (WebEx/site visits/phone calls). 	<ol style="list-style-type: none"> 1. Submission of five case studies of ‘innovative practice’ to the national team. 2. Submission of monthly data using the NHS Safety Thermometer from each organisation in the collaborative. 3. Well-defined plans for scale up to the remaining organisations in the region, including plans to work collaboratively with commissioners. 4. Identification of teams to put forward for national awards at a Summit event at the end of the pilot. 5. Plans to publish the work. 	<ol style="list-style-type: none"> 1. All organisations in the region to have participated in the CQUIN for collecting NHS ST data monthly. 2. Engagement with Clinical Commissioning Groups to raise awareness of ‘harm-free’ care programme and the NHS Safety Thermometer CQUIN (e.g. attendance at the Safe Care work stream meeting for commissioners, attendance at CQUIN master classes in which the details of the CQUIN were explained to commissioners from each region). 3. Review regional level data. 4. Publication of the results of the QIPP Safe Care programme of work. 5. Evidence of regional planning for delivery of improvement for the 2013/14 CQUIN. 	<ol style="list-style-type: none"> 1. All organisations participating in the 2013/14 CQUIN to aim to achieve 50% improvement in reduction of the four harms by March 2014. 2. Evidence of the harm-free care programme in Trust’s Quality Accounts and/or Trust Board reports. 3. All CCGs commissioning harm-free care locally. 4. All CCGs and organisations to have systems in place to embed ‘harm-free’ care into contracts and to embed into the new NHS and social care structures. 5. Evidence of support to assist organisations who have not achieved 50% improvement.

Table 1: Safety Express key deliverables and review points for regions, determined in advance

<i>Site characteristic</i>	<i>Descriptor</i>	<i>Survey respondents*</i>
Organisation (n=133)	Acute trust	63.9%
	Community trust	24.1%
	Mental health trust	2.3%
	Primary care trust	7.5%
	Strategic Health Authority	6.0%
	Other	4.6%
Staff level banding** (n=134)	Bands 1-4	0.7%
	Bands 5-6	10.4%
	Bands 7-8	61.9%
	Above Band 8	28.4%
	Other	2.1%
Regional cluster (n=134)	North	26.9%
	Midlands/East of England	26.9%
	London	6.7%
	South East Coast	9.7%
	South Central	21.6%
	South West	6.0%
	Prefer not to say	6.0%

Table 2: Survey respondent characteristics

*Some respondents chose more than one option to describe their organisation, banding, and region.

** Most jobs in the NHS are covered by the Agenda for Change (AfC) pay scales. This covers all staff except doctors, dentists and the most senior managers. The AfC job evaluation system determines a point score which is used to match jobs to one of the nine pay bands and determine levels of basic salary (ref: <http://www.nhscareers.nhs.uk/explore-by-career/nursing/pay-for-nurses/>.)

Region	Population ¹ (millions)	Budget ² (in billions)	Collaborative participation			Alignment with workstream goals ⁴					
			Number of host organisations ³ participating in Safety Express	LS1 ⁴ Attendees	LS2 Attendees	LS3 Attendees	Baseline Assessment	Review 1	Review 2	Review 3	Final Review
				(Jan 11)	(Mar 11)	(Jun 11)	(Sep - Dec 10)	(April 11)	(Sep 11)	(Sep 12)	(Mar 13)
1	6.7	£12	15	112	85	72	Amber	Red	Red	Amber	Amber
2	2.5	£4.7	6	31	24	19	Red	Red	Red	Red	Red
3	4.9	£9.3	5	27	25	7	Red	Red	Red	Red	Red
4	4.1	£7.7	10	39	55	32	Amber	Amber	Amber	Red	Red
5	5.3	£5.2	9	87	45	18	Amber	Amber	Red	Red	Red
6	5.4	£10.1	9	22	28	31	Amber	Amber	Green	Green	Green
7	7.4	£13.9	10	75	59	60	Red	Red	Green	Green	Amber
8	4.1	£7.7	22	70	53	43	Amber	Amber	Amber	Amber	Red
9	3.9	£7.3	11	31	22	48	Red	Amber	Red	Red	Red
10	4.9	£9.3	31	81	77	118	Red	Red	Red	Red	Amber

Table 3: Regions' participation in the collaborative and alignment with programme goals

¹ Population in millions rounded to one decimal place; ² Allocation of spend to the nearest £100,000 to each SHA region in FY 2010/11; ³ A host organisation was defined as the lead organisation who collaborated with other organisations across the health economy. ⁴ LS = learning session




Figure 1a: Number of organisations submitting data over time*

*NHS Trusts submitting NHS Safety Thermometer data over time, from the start of the Safety Express programme ('Phase 1') through to end of the first period of incentivised data collection ('Phase 2'). Bar height represents the total unique NHS Trusts submitting within the month. In January 2011, 12 organisations submitted. In March 2013, this had risen to 252 organisations.




Figure 1b: Number of patient entries submitted over time.*

*Number of individual patient-level entries submitted to the NHS Safety Thermometer over time from the start of the Safety Express programme (‘Phase 1’) through to end of the first period of incentivised data collection (‘Phase 2’). Bar height represents the total patients submitted within the month. In January 2011, 712 patients were surveyed and their data submitted against the ‘harm-free’ Care measure. In March 2013, this was 98,372 patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Timeline of key political and policy events 2009-2012




Figure 3a: Percent harm-free care over time for patient entries submitted from the initial Safety Express ('Phase 1') cohort in January 2011 over time, until the end of the incentivised data collection period ('Phase 2') plotted as a P prime chart*

*P' Chart showing percent of patients from the initial cohort of Safety Express ('Phase 1') organisations experiencing harm-free care as defined by the NHS Safety Thermometer, presented over time. These data are plotted as a P prime (P') chart; a type of control chart used for time-series data with a large denominator. Individual data points represent the % of patients in the cohort who received harm-free care each month; in January 2011 this was 85.1%. In March 2013, this was 91.4%. Control limits are used to apply control chart rules to detect special cause. The original plot of these data highlighted three distinct phases, indicated by the readjusted mean line.




Figure 3b: Percent harm-free care over time for patient entries from all submitting acute care trusts over time, from the beginning of the ‘Safety Express’ period (‘Phase 1’) to the end of the incentivised data collection period (‘Phase 2’) plotted as a P prime chart*

*P’ Chart showing percent of patients experiencing harm-free care (as defined by the NHS Safety Thermometer) whilst an inpatient in an acute bed, at any submitting NHS Trust, presented over time. Similar to Figure 3a, these data are plotted as a P prime (P’) chart. Individual data points represent the % of patients who received harm-free care each month; in January 2011 this was 86.5%. In March 2013, this was 92.2%. Control limits are used to apply control chart rules to detect special cause. The original plot of these data highlighted three distinct phases, indicated by the readjusted mean line.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

1 References

- 1 Landrigan CP, Parry GJ, Bones CB, et al. Temporal trends in rates of patient harm resulting from medical care, *N Engl J Med* 2010;363:2124-34.
- 2 Provenzano A, Rohan S, Trevejo E, et al. Evaluating inpatient mortality: a new electronic review process that gathers information from front-line providers, *BMJ Qual Saf* 2015;24:31-7.
- 3 Hogan H, Healey F, Neale G, et al. Preventable deaths due to problems in care in English acute hospitals: a retrospective case record review study, *BMJ Qual Saf* 2012;21:737-45.
- 4 Berwick DM, Calkins DR, Joseph McCannon C, et al. The 100 000 lives campaign: Setting a goal and a deadline for improving health care quality, *J Am Med Assoc* 2006;295:324-7.
- 5 Benning A, Ghaleb M, Suokas A, et al. Large scale organisational intervention to improve patient safety in four UK hospitals: mixed method evaluation, *BMJ* 2011;342:d195 doi:10.1136/bmj.d195 [published Online First: Feb 3].
- 6 Benning A, Dixon-Woods M, Nwulu U, et al. Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase, *BMJ* 2011;342:d199.
- 7 Krumholz HM, Bradley EH, Nallamothu BK, et al. A Campaign to Improve the Timeliness of Primary Percutaneous Coronary Intervention: Door-to-Balloon: An Alliance for Quality, *J Am Coll Cardiol Intv* 2008;1:97-104.
- 8 Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study, *The Lancet infectious diseases* 2012.
- 9 Bion J, Richardson A, Hibbert P, et al. 'Matching Michigan': a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England, *BMJ Qual Saf* 2012.
- 10 Forster AJ, Worthington JR, Hawken S, et al. Using prospective clinical surveillance to identify adverse events in hospital, *BMJ Quality & Safety* 2011;20:756-63.
- 11 Ozieranski P, Robins V, Minion J, et al. Running a hospital patient safety campaign: a qualitative study, *Journal of Health Organization and Management* 2014;28:562-75.
- 12 Pronovost PJ, Goeschel CA, Marsteller JA, et al. Framework for patient safety research and improvement, *Circulation* 2009;119:330-7.
- 13 Dixon-Woods M, Bosk CL, Aveling EL, et al. Explaining Michigan: developing an ex post theory of a quality improvement program, *Milbank Q* 2011;89:167-205.

- 1
2
3 14 Dixon-Woods M, McNicol S, Martin GP. Ten challenges in improving quality in health care:
4 lessons from the Health Foundation's programme evaluations and relevant literature, *BMJ Quality &*
5 *Safety* 2012;21:876-84.
6
7
8 15 Aveling EL, Martin G, Armstrong N, et al. Quality improvement through clinical communities:
9 eight lessons for practice, *J of Health Org and Mgt* 2012;26:158-74.
10
11 16 Soo S, Berta W, Baker GR. Role of champions in the implementation of patient safety practice
12 change, *Healthc Q* 2009;12:123-8.
13
14 17 Fuller C, Michie S, Savage J, et al. The Feedback Intervention Trial (FIT) - Improving Hand-
15 Hygiene Compliance in UK Healthcare Workers: A Stepped Wedge Cluster Randomised Controlled
16 Trial, *PLoS ONE* 2012;7.
17
18 18 Dixon-Woods M, McNicol S, Martin G. Ten challenges in improving quality in healthcare: lessons
19 from the Health Foundation's programme evaluations and relevant literature, *BMJ Quality Safety*
20 2012;21:876-84.
21
22
23 19 Power M, Tyrrell PJ, Rudd AG, et al. Did a quality improvement collaborative make stroke care
24 better? A cluster randomized trial, *Implementation Science* 2014;9:40-.
25
26
27 20 Lecko C. Patient safety and nutrition and hydration in the elderly. 2013;2014.
28
29
30 21 Morris-Thompson T, Aldred V, Clark N, et al. Safety Express: a strategic health authority's
31 approach, *British journal of nursing* 2012;21:677-83.
32
33 22 Health and Social Care Information Centre. NHS Safety Thermometer. 2013;2014.
34
35 23 Hulscher ME, Schouten LM, Grol RP, et al. Determinants of success of quality improvement
36 collaboratives: what does the literature show? *BMJ Quality & Safety* 2012.
37
38 24 Institute for Healthcare Improvement. The Breakthrough Series: IHI's Collaborative Model for
39 Achieving Breakthrough Improvement. IHI Innovation Series white paper. *Boston: Institute for*
40 *Healthcare Improvement* 2003.
41
42 25 Dixon-Woods M, Baker M, Charles J, et al. Culture and behaviour in the English National Health
43 Services: overview of lessons from a large multi-method study, *BMJ Qual Saf* 2013;23:106-15.
44
45 26 Charmaz K. Constructing grounded theory: A practical guide through qualitative analysis. London:
46 Sage 2006.
47
48 27 Glaser B, Strauss A. The discovery of grounded theory. Hawthorne, NY: Aldine Publishing
49 Company 1967.
50
51 28 Altheide DL. Ethnographic content analysis. In: Lewis Beck MS, Bryman A, Liao TF, eds. The
52 Sage Encyclopaedia of Social Science Research Methods. Thousand Oaks, Ca: Sage 2004.
53
54
55
56
57
58
59
60

- 1
2
3 29 Power M, Fogarty M, Madsen J, et al. Learning from the design and development of the NHS
4 Safety Thermometer, *Int J Qual Health Care* 2014;26:287-97.
5
6
7 30 Schouten LM, Hulscher ME, van Everdingen JJ, et al. Evidence for the impact of quality
8 improvement collaboratives: systematic review, *BMJ* 2008;336:1491-4.
9
10 31 Needham DM, Sinopoli DJ, Dinglas VD, et al. Improving data quality control in quality
11 improvement projects, *Int J Qual Health Care* 2009;21:145-50.
12
13 32 Benn J, Burnett S, Parand A, et al. Studying large-scale programmes to improve patient safety in
14 whole care systems: Challenges for research, *Soc Sci Med* 2009;69:1767-76.
15
16 33 Pronovost PJ, Nolan T, Zeger S, et al. How can clinicians measure safety and quality in acute care?
17 *Lancet* 2004;363:1061-7.
18
19
20 34 Dixon-Woods M, Leslie M, Tarrant C, et al. Explaining Matching Michigan: an ethnographic
21 study of a patient safety program, *Implement Sci* 2013;8:70.
22
23 35 McKee L, Charles K, Dixon-Woods M, et al. New” and distributed leadership in quality and safety
24 in healthcare, or “old” and hierarchical? An interview study with strategic stakeholders *Journal of*
25 *Health Services Research and Policy* 2013;DOI: 10.1177/1355819613484460.
26
27
28 36 Øvretveit J, Bate P, Cleary P, et al. Quality collaboratives: lessons from research, *Quality and*
29 *safety in health care* 2002;11:345-51.
30
31
32 37 Martin G, Armstrong N, Dixon-Woods M, et al. Professionalism Redundant, Reshaped, or
33 Reinvigorated? Realizing the ‘Third Logic’ in Contemporary Healthcare, *Journal of Health and*
34 *Social Behaviour* 2015;Published online before print.
35
36 38 Roland M, Dudley RA. How Financial and Reputational Incentives Can Be Used to Improve
37 Medical Care, *Health Serv Res* 2015;50:2090-115.
38
39
40 39 Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and
41 healthcare outcomes. *Cochrane database of systematic reviews (Online)* 2012;6.
42
43 40 Brown JR, Solomon RJ, Sarnak MJ, et al. Reducing Contrast-Induced Acute Kidney Injury Using
44 a Regional Multicenter Quality Improvement Intervention. *Circulation: Cardiovascular Quality and*
45 *Outcomes* 2014.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

A multi-method study of a large-scale programme to improve patient safety using a harm-free care approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011886.R1
Article Type:	Research
Date Submitted by the Author:	31-May-2016
Complete List of Authors:	Power, Maxine; Salford Royal NHS Foundation Trust, HAELO Brewster, Elizabeth; University of Lancaster, Medical Education Parry, Gareth; Harvard Medical School, Brotherton, Ailsa; Salford Royal NHS Foundation Trust, HAELO Minion, Joel; University of Bristol, Social Medicine Ozieranski, Piotr; University of Bath McNicol, Sarah; Manchester Metropolitan University Department of Exercise and Sport Science Harrison, Abigail; Salford Royal NHS Foundation Trust, Haelo DixonWoods, Mary; University of Leicester, Health Sciences
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health policy
Keywords:	patient safety, measurement, improvement programmes, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, quality improvement collaboratives, mixed-methods

SCHOLARONE™
Manuscripts

only

A multi-method study of a large-scale programme to improve patient safety using a harm-free care approach

AUTHORS

Maxine Power¹
Liz Brewster²
Gareth Parry³
Ailsa Brotherton¹
Joel Minion⁴
Piotr Ozieranski⁵
Sarah McNicol⁶
Abigail Harrison¹
Mary Dixon-Woods^{7*}

¹Haelo, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK

²Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YW, UK

³Institute for Healthcare Improvement, 20 University Rd, Cambridge, MA 02138, United States

⁴Data to Knowledge Group, School of Social and Community Medicine, University of Bristol, Bristol BS8 2BN, UK

⁵Department of Social and Policy Sciences, University of Bath, Bath, BA2 7AY, UK

⁶Education and Social Research Institute, Manchester Metropolitan University, Crewe Green Road, Crewe, Cheshire, CW1 5DU

⁷SAPPHIRE Group, Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK

*Corresponding author. *Rand Professor of Health Services Research, Institute of Public Health*

Forvie Site, University of Cambridge School of Clinical Medicine, Box 113 Cambridge Biomedical Campus, Cambridge CB2 0SR. Tel: + 44 116 2297262 email: md753@medschl.cam.ac.uk

Keywords: Quality improvement collaboratives; Quality Improvement, Implementation, Patient Safety, National Health Service

Abstract

Objectives: We aimed to evaluate whether a large-scale two-phase quality improvement programme achieved its aims and to characterise the influences on achievement.

Setting: National Health Service (NHS) in England.

Participants: NHS staff.

Interventions: The programme sought to: 1) develop a shared national, regional and locally aligned safety focus for four high-cost, high volume harms; 2) establish a new measurement system based on a composite measure of “harm-free” care; 3) deliver improved outcomes. Phase 1 involved a quality improvement collaborative intended to involve 100 organisations; phase 2 used financial incentives for data collection.

Measures: Mixed-method evaluation of the programme. In Phase 1, analysis of regional plans and of rates of data submission and clinical outcomes reported to the programme. A concurrent process evaluation was conducted of Phase 1, but only data on submission rates and clinical outcomes were available for Phase 2.

Results: A context of extreme policy-related structural turbulence impacted strongly on Phase 1. Most regions’ plans did not demonstrate full alignment with the national programme; most fell short of recruitment targets and attrition in attendance at the collaborative meetings occurred over time. Though collaborative participants saw the principles underlying the programme as attractive, useful and innovative, they often struggled to convert enthusiasm into change. Developing the measurement system was arduous, yet continued to be met by controversy. Data submission rates remained patchy throughout Phase 1 but improved in reach and consistency in Phase 2 in response to financial incentives. Some evidence of improvement in clinical outcomes over time could be detected but was hard to interpret owing to variability in the denominators.

Conclusions: These findings offer important lessons for large-scale improvement programmes, particularly when they seek to develop novel concepts and measures. External contexts may exert far-reaching influence. The challenges of developing measurement systems should not be underestimated.

Strengths

- The multi--method design enabled a holistic evaluation.
- The study reveals the impact of policy and structural turbulence on ability to achieve change in health systems.
- The importance of a rigorous development phase for improvement programmes, including significant investment upfront in measurement and data systems, was identified.

Weaknesses

- The process evaluation of the first phase of the programme may have been biased towards those with more positive views.
- The absence of a process evaluation for the second phase of the programme is a further limitation.
- Independent data on clinical outcomes were not available, and the evaluation thus relied on data collected by the programme itself.

Introduction

How best to ensure the safety of patients continues to challenge health systems worldwide.[1-3] Recent years have seen multiple efforts to secure improvements. Some have multiple safety targets and seek generalised strengthening of organisational systems, processes and cultures,[4-6] while others target specific areas of harm or practice.[7-9] Whatever their form, improvement programmes typically measure outcomes one by one, with incidence for each – for example central venous catheter bloodstream infections or unplanned readmissions to hospital - reported singly and separately, rather than in terms of how many harms each person suffered. Most also focus on specific, well-bounded healthcare settings and measure harms that are assumed to be attributable to the care provided in those environments.

Some (though not all) patient safety programmes have reported welcome successes in relation to specific harms. From the patient's perspective, however, a focus on single outcomes in well-bounded healthcare settings may be deficient, potentially obscuring individuals' experiences across pathways of care and their exposure to concatenations of multiple adverse events.[10] Addressing harms singly also has other unintended consequences, including the reinforcement of disciplinary boundaries. Infection control nurses may, for example, work in isolation from tissue viability nurses with the same patients. Thus, a potentially more useful approach to safety might focus on the extent to which patients escape all possible harms and could thus be deemed to have experienced care that is "harm-free". In this article, we report a study of a large-scale programme seeking to promote an innovative approach to harm-free care in England.

The harm-free care programme

The programme had three major goals:

- Develop a shared national, regional and locally aligned safety focus for four high-cost, high volume harms (venous thrombo-embolism (VTE), pressure ulcers, urinary tract infection in patients with urinary catheters, and falls). These four harms were selected because they account for a large proportion of all avoidable injury to patients and share many underlying factors (e.g. mobility, medication management, nutrition, hydration) relating to basic patient care, yet may involve trade-offs in managing risk;[1, 11]
- Establish a measurement system based on the principle that a new patient-centred measure that would "bundle" harms into a single, composite score of harm-free care would bring new insights into harm rates, enable clinical teams to identify and recognise where problems lay, and motivate local improvement;

- Deliver improved clinical outcomes, with a specific objective of ensuring that 95% of patients would be harm-free.

Run as part of the Department of Health's Quality, Innovation, Productivity and Prevention (QIPP) 'Safe Care' workstream,[12] the programme was led by a dedicated national programme team. The programme did not seek to develop new technical interventions for managing the four harms nor to set targets, but instead sought to: ensure that addressing the four harms together for each patient was identified as a priority for organisations, support organisations and teams in implementing existing good practice in relation to the four harms, and provide a well-founded means of surveillance, monitoring and feedback on harm-free care.

It ran in two distinct phases. The first phase ran September 2010 to April 2012, including a three-month preparatory period at the beginning (September 2010-December 2010) and a six-month maintenance period at the end (October 2011-April 2012). This first phase sought to pilot an approach to measuring and improving patient safety, to support a cohort of organisations to implement and test it, and ultimately to prepare the way for the subsequent use of the approach across all care settings in England. To achieve these aspirations, the national team undertook an intensive period of programme design, refinement of operational definitions, cycles of testing and learning, and developing and modifying a data collection tool for harm-free care.

This tool, which came to be known as the NHS Safety Thermometer, sought to enable collection of data that would both be comparable at a national level and useful in local improvement work,[13] and that would balance accurate measurement and standardised definitions with straightforward data collection methods that did not burden staff. The design period was followed by work to implement the programme through regional and local partnerships (Table 1), much of it organised through a voluntary quality improvement collaborative known as Safety Express.

Use of the collaborative model[14] was based on the theory that it would facilitate rapid shared learning and the mobilisation of collective cross-multidisciplinary action.[15] Consistent with the BreakThrough Series collaborative approach,[16] Safety Express involved three learning events where participants across the regions came together and action periods during which participants were asked to implement improvement activities (e.g. setting up data collection systems and implementing Plan-Do-Study-Act cycles). Participants were recruited through the 10 Strategic Health Authority (SHA) regions then extant in the English NHS. Each region was asked to engage 10 participating organisations serving a local population, and each of these organisations was asked to ensure that 10 staff members (primarily front-line clinicians) attended the learning events and that they tested the NHS Safety Thermometer in a relevant caseload. The work of clinical teams in undertaking these activities was supported by the regional and national teams, as well as by online

resources and detailed guidance on good practice interventions and on how to submit and interpret local data. Participating organisations were asked to collect data on four wards (acute) or on their caseloads (non-acute) on one day per month using the NHS Safety Thermometer and to submit it to a central data collection facility. A six-month maintenance period during which organisations were asked to continue submitting data followed the completion of Safety Express in September 2011. Some support, albeit limited, was available to organisations on request during the maintenance period.

The second phase of the programme ran April 2012 to March 2013, when it expanded beyond the original participants to include all settings providing care for NHS patients in England. An important characteristic of this phase is that financial incentives were offered to all NHS organisations in England to submit data on 100% of patients on one day per month using the NHS Safety Thermometer. Only limited improvement support was available: the collaborative did not continue, though access to online resources remained, and some limited support was available from the NHS Institute for Improvement and Innovation up to March 2013. Some locally organised (not nationally coordinated) support activity also took place.

Study aim

The available evidence suggests that large-scale programmes may offer some important advantages over single-organisation efforts[17] by supporting the infrastructure for improvement, including the development of well-founded interventions and data systems[18] as well as activating the social conditions, peer-norming effects and shared learning most likely to foster change[15, 19, 20] and enabling change at scale. A growing body of evidence now points to the features essential to the success of such programmes, including shared goals among participants, clinician engagement, clinical champions, and the importance of well-designed, theoretically sound interventions[5, 21-23]. However, large-scale improvement programmes continue to show a mixed picture of success, with many reporting disappointingly modest (or no) improvements in implementation of evidence-based interventions in practice.[24, 25] These findings suggest that much remains to be learned about these complex interventions,[26] for example regarding contextual influences,[27] programme design and implementation,[28] measurement,[29, 30] and sustainability beyond project timelines.[31]

With the aim of addressing these gaps in knowledge and improving the evidence-base for future large-scale improvement programmes, particularly when they involve novel approaches and measures, our study sought to assess how far the harm-free programme met its three aims and to identify and characterise the influences on the achievement of these aims.

Methods

We conducted a multi-method evaluation “wrapped around” the programme,[32] rather than a research study that set out to test specific hypotheses. During Phase 1 of the programme, we used a combination of data collected by the programme itself and an independent process evaluation. The programme data included an analysis conducted by the national team of the extent to which regional strategy was aligned to national goals, information on the number of organisations that were submitting data on the four harms, and the data on clinical outcomes (the four harms) submitted by participating organisations. As part of a wider study of quality and safety in the NHS,[33] we also conducted a concurrent process evaluation of Safety Express (the quality improvement collaborative that ran during Phase 1), using interview, observational, questionnaire and documentary data. The process evaluation was used as part of a convergent design directed towards obtaining different but complementary data and thus developing a more complete understanding of the programme at multiple levels.[34] Approval for the process evaluation was obtained from an NHS REC. Signed consent was obtained for interviews.

For reasons of resource, only the programme data on submission rates and clinical outcomes submitted by the participating organisations were available for Phase 2. The organisations submitting data changed over time (especially between Phase 1 and Phase 2), leading to denominators that increased in size and diversity over time. In order to identify whether collaborative participation had an effect, we undertook a subgroup analysis of the 12 organisations that submitted data consistently from January 2011 to March 2013.

All quantitative data were collected and analysed by the programme team; all qualitative data were collected and analysed by an evaluation team independent of programme team (Boxes 1 and 2). The data were analysed separately and then synthesised thematically.[35]

Box 1: Quantitative data

Programme goal	Data	Analysis
Delivery of required programme outputs: inclusion of the four harms in each region’s system-level strategy plans and QIPP improvement programmes.	Each region’s progress extracted from plans and mapped on four occasions using a categorical rating scale, used to assess achievement of programme goal of a shared national, regional and locally aligned safety focus for the four harms.	A judgment was made by the programme team to determine whether the region was achieving four or more of the milestones (green), two to three (amber) or one or less (red).
Team engagement: participation in the collaborative, delivery of the	The number of participating organisations and the number of attendees each region sent	Count data displayed as descriptive statistics and percentages.

<p>required programme outputs and NHS Safety Thermometer data collection.</p>	<p>to each learning session in Safety Express was recorded, used to assess achievement of goal of a shared national, regional and locally aligned safety focus for the four harms.</p>	
<p>Harm-free care clinical outcomes: absence of all four harms at the individual patient level</p>	<p>For each patient, data were collected by local clinicians on four outcomes (pressure ulcers, falls, urinary tract infection in patients with urinary catheters, and VTE) and submitted using the NHS Safety Thermometer, used to monitor progress towards the programme of improved clinical outcomes.</p> <p>To allow for variation in organisations submitting data over time, two cohorts were formed:</p> <p>1) Data from acute patients from the initial, Phase 1 Safety Express organisations consistently submitting between January 2011 and March 2013</p> <p>2) Data from acute patients from all organisations submitting at any time between January 2011 and March 2013.</p>	<p>The composite measure of harm-free care was plotted over time using a control chart. To take account of over-dispersion, due to the large sample size, a P' control chart was used. Standard control chart rules were applied to indicate special and common cause variation and when a shift in the average occurred. Statistical analysis was performed using R-2.15.1 for Windows (http://cran.r-project.org/bin/windows/base/old/2.15.1/).</p>

Box 2: Process Evaluation (Phase 1 only)

Method	Data	Analysis
<p>Semi-structured interviews. A prompt guide was used to elicit experiences and views of the programme from stakeholders who were purposively sampled to represent different constituencies (e.g national, regional and local). Participants were recruited through email coordinated by the national team. Theoretical sampling was not possible due to the nature of recruitment; instead all those who agreed to be interviewed over a defined time-frame were interviewed. It was not possible to assess theoretical saturation formally. Interviews were audio-recorded and transcribed.</p>	<p>Interviews with seven QIPP national team members, six local coordination leads and 11 programme participants. The local programme co-ordination leads were more senior nursing staff, located in four of the 10 Strategic Health Authorities. The programme participants interviewed were mainly nursing staff with responsibility for clinical governance, tissue viability, or patient safety and were based in eight of the 10 regions. These data were used to assess influences on the programme's achievement of its goals of shared goals and establishment of a measurement system.</p>	<p>Analysis was based on the constant comparative method, facilitated by NVivo software[36, 37]. Open codes were generated through close reading of transcriptions. Reflection and interpretation was used to produce a higher level of abstraction and thematic categories. Coding of transcripts was supported by NVIVO 8 software.</p>
<p>Observations. Observers took detailed field notes and held debrief sessions, which were audio-recorded and transcribed.</p>	<p>Ethnographic observations to assess the experience of participating in the programme were conducted at Six Safety Express learning events.</p>	<p>As above</p>
<p>Survey. Based on the observational and interview data, an online survey was developed and circulated to all learning event participants. Covering implementation of the programme, data measurement and organisational involvement, the majority of the 40 survey questions were multiple-choice or Likert scale, with four free-text questions used to elicit more in-depth responses.</p>	<p>The survey received 157 anonymised responses; because of the method of email distribution, it was not possible to calculate a response rate. A diverse selection of respondents completed the survey (Table 2), reflecting those participating in the project. These data were used to assess influences on the programme's achievement of its goals.</p>	<p>Descriptive analyses of the survey data, with free-text responses coded using content analysis.[38]</p>
<p>Documents. Project documentation and key policy documents were purposively sampled.</p>	<p>~20 relevant documents, including policy materials, were collected from the programme team and from QIPP and other websites. These were used to gather information about the programme and possible contextual influences.</p>	<p>Review and summary.</p>

Results

The process evaluation, which focused on Phase 1 only, involved 24 interviews, 157 survey responses, 48 hours of observation, and around 20 documents. Data on clinical outcomes were submitted by participating organisations over both phases on the programme, though the composition of the contributing organisations and the consistency with which individual

1
2
3 organisations submitted data varied over time (Figs 1a and 1b). Quotations are numbered to indicate
4 different participants and preserve anonymity.
5
6
7

8
9
10 **Achievement of programme aim 1: Develop a shared national, regional and locally aligned safety**
11 **focus for the four harms**

12
13 Evidence on the development of a shared national, regional and locally aligned safety focus for the
14 four harms during Phase 1 was assessed through an analysis of the plans that regions submitted to
15 the national programme team. A mixed picture emerged. Substantial variability (Table 1) was
16 evident in how well the regions' plans were aligned with those of the national programme. Only two
17 of the ten regions' plans were rated as 'green' on the rating scale by September 2011 (almost nine
18 months after the start of the programme) and only one organisation maintained this for over a year
19 (Table 3).
20

21
22 All 10 regions signed up to participate in the Safety Express collaborative, but only two were able to
23 reach the goal they were set of recruiting 10 participating organisations (range 5-31). None was able
24 to provide 100 participants at each learning event (range 22-118), meaning that the goal of enrolling
25 1000 front-line clinicians was not reached. In seven regions, attrition occurred in the number of
26 delegates attending the learning events as the programme progressed.
27

28
29 Interviews showed that many (though not all) participants saw the principles underlying the
30 programme as attractive, useful and innovative. Much support was expressed for the programme
31 principle of taking a holistic approach to harm: almost two-thirds (64%) of survey participants
32 strongly agreed or agreed that the four harms chosen were the most important for their
33 organisation to address, and interview participants were also generally positive about the approach
34 to harm-free care. Survey and interview data suggested that participants generally valued the
35 collaborative features of the programme, with the learning sessions and encouragement from the
36 national team seen as particularly useful. Observations at the Safety Express learning sessions found
37 that participants demonstrated considerable enthusiasm, and that the sessions helped to build
38 relationships and share learning, ideas and practical tools.
39
40
41
42
43
44
45
46
47
48
49

50
51
52 *I mean we could bounce ideas off them, say we have thought about this, is anybody else*
53 *doing something similar who we can talk to? So they have got that information to signpost*
54 *us. (Learning session participant I-05)*
55

56
57 However, the ambition of the programme daunted some participants. Just under half (44.6%) of
58 survey respondents reported that the programme was greeted with 'initiative fatigue' in their
59 organisation. Though nearly three-quarters (73.2%) reported that achieving 'harm-free' care was a
60

1
2
3 realistic goal for the NHS, just over a third (34.8%) thought their organisation was close to attaining
4 it. Translating the enthusiasm generated by collaborative activities into local action remained a
5 challenge for many.
6
7

8
9 *The ethos of it is obviously just what it should be, but how achievable it is I am not sure.*
10 *(Learning session participant I-06)*

11
12 *Brilliant for networking and we all left feeling positive [...] it was the sustainability following*
13 *the events [that was] difficult. Because obviously you leave the room full of ideas and you go*
14 *back to your everyday work and... it's very difficult to keep it going, I have to say. (Learning*
15 *session participant)*
16

17
18 The most profound influence on the ability of regions and organisations to engage with the
19 programme appeared to be the context of extreme policy turbulence and structural change.
20 Documentary analysis of the 2009-12 policy context (Fig. 2) identified the transformations of the
21 NHS architecture associated with the Health and Social Care Act (2012), with the effects evident
22 both before (in anticipation of) and after the passing of the legislation. Alongside many changes, a
23 new national commissioning board was created (NHS England) and the 10 Strategic Health
24 Authorities were replaced by four regional offices of NHS England. The national bodies that had
25 supported system change were decommissioned (the NHS Institute in March 2013 and the National
26 Patient Safety Agency in June 2012). Loss of senior leadership at the national and regional level
27 contributed to voids of coordination and communication during the programme. Interviews with the
28 programme showed that in all but one region, the problems faced in delivering the programme
29 caused by external and internal turbulence necessitated implementation of a recovery plan and the
30 establishment of direct communication between the national team and the participating teams
31 rather than through the regions.
32
33

34 35 36 37 38 39 40 41 **Achievement of programme aim 2: Establish a measurement system to understand the burden of** 42 **the four harms** 43 44

45
46 The programme largely succeeded in its aim of establishing a measurement system, but interviews
47 and observations showed that the process of its development was effortful and it continued to
48 generate considerable controversy throughout the programme.
49

50
51 Interviews, documents and observations found that a prototype of the NHS Safety Thermometer
52 data collection tool was developed by the national programme team during the design period of
53 Phase 1, and refined iteratively thereafter. Intended to be used by frontline staff, who were asked to
54 collect data on the four harms by reviewing patients' records and examining and speaking to the
55 patient harms,[39]the tool enabled entry of data through an online spreadsheet. It provided instant
56 data display for the participating clinical teams, and, through a merge function, supported
57
58
59
60

1
2
3 aggregation to give whole organisational, regional and national datasets. Though rates of each of the
4 four harms could be viewed separately, a novel feature of the NHS Safety Thermometer was its
5 ability to generate a composite measure of “harm-free” care to indicate the proportion of patients
6 who had not experienced any of the four harms.
7
8

9
10 During Safety Express, the 10 regions were asked to coordinate collection of data using the NHS
11 Safety Thermometer from ten organisations from their region. Each of these 10 organisations was
12 asked to collect data and submit on four wards (acute) or caseloads (non-acute) on one day per
13 month. In interviews, many Safety Express participants saw the NHS Safety Thermometer as
14 innovative, providing a useful and valuable dataset that could be used to drive improvements and
15 provide evidence of progress. They reported that the tool had several advantages in comparison
16 with some available methods of measurement, including the potential that the tool provided for
17 intervening and improving care on the spot. Some participants reported that working across all four
18 harms helped to avoid duplication, both of data collection and effort.
19
20
21
22
23
24

25
26 *The sheer number of nurses that have said: what is fabulous about it is that it means that I*
27 *can improve patient care while the patient is right here, still in the bed and still when I can do*
28 *something about it [...] When I did the Safety Thermometer it was clear the [patient] had not*
29 *had a VTE assessment done so I got the junior doctor to do it for them. (National team*
30 *member I-22)*
31

32
33 *My understanding was that [the harms] selected themselves really because they were the*
34 *biggest category of avoidable harms in healthcare and from that point of view I think they*
35 *were the right ones to focus on. (Local organiser I-05)*
36

37 Some participants (including around 20% of survey respondents) commented on the value of having
38 shared definitions and being able to collect comparable data on harms across organisations.
39

40
41 *The consistent approach across the country so we measure apples and apples. [Survey]*
42

43 *[NHS Safety Thermometer] is the first time that we have actually been nationally able to*
44 *measure something in the same way to the same definition... I don't think that has happened*
45 *in anywhere in Europe. (Local organiser I-15)*
46
47

48 However, developing and deploying the NHS Safety Thermometer was not without substantial
49 challenges. The time required to develop the tool was lengthy, much greater than the programme
50 team had initially anticipated; modifications were still being made to the data collection instrument
51 late in 2011, almost eleven months after the start of the collaborative. Questions and disagreement
52 about the inclusion of the harms and their exact definition dogged the development of the
53 programme, in particular, as shown by observations and interviews, by introducing delays while
54 consensus was sought. This was particularly true of the inclusion of the measure relating to urinary
55 tract infection in patients with urinary catheters, which some participants disputed or reported was
56
57
58
59
60

1
2
3 unclear. Over one in 10 (11.8%) of survey respondents felt that the inclusion of this measure in the
4 programme was not soundly based in scientific evidence, compared with just 2% feeling that there
5 was no scientific basis to include VTE.
6
7

8
9 *I think the other thing with falls and pressure ulcers is that there are quite clear definitions*
10 *that everyone agrees on. For catheter associated UTIs it has not been the same... That has*
11 *created quite a lot of confusion. [Local organiser I-15]*
12

13
14 *Because of some of the questions around the measurement piece, because of the questions*
15 *around – well what does the definition for UTI look like in my organisation compared to*
16 *yours? Very valid conversations but nonetheless quite stalling [National team member I-18]*
17

18 Some participants, for example in the sessions we observed as well as in interviews, expressed a very
19 strong view that a national measurement strategy was neither useful nor appropriate. Organisations
20 and individuals were often already using their own local definitions of some or all of the four harms,
21 and had established methods of data collection and data display (though these were largely from
22 incident reporting systems). Participants did not always demonstrate consensus that the four harms
23 chosen by the programme were the most important focus for improvement efforts in their own
24 organisations.
25
26
27
28

29
30 *The difficulty with it is that if we've already got a system and a process in place in some*
31 *organisations to measure what they're doing against falls, pressure ulcers, whatever,*
32 *individually, the link hasn't been there. (Local organiser I-24)*
33

34 The number of updates to the tool over the course of Safety Express in response to feedback caused
35 some frustration among participants, who did not always appreciate the developmental nature of
36 the first phase of the programme. Participants also complained, in interviews and in the survey, that
37 the tool was not as easy to use as intended. The extent to which data collection would need to be
38 supported was initially under-estimated by the national team; some months in, they reported that it
39 became clear that there was a skills gap in relation to measurement in many participants, who were
40 often inexperienced in collecting or using data for improvement. Documents and interviews showed
41 that the produced a suite of materials to support learning and implementation and delivered a series
42 of learning workshops across the country on measuring improvement, including technical capability
43 (actual use of the data tool). In the survey, half (50.0%) of respondents described the tool as
44 'straightforward,' but nearly half (44.3%) felt that data collection was a major burden. Some teams
45 struggled to integrate the new data collection into their existing practice.
46
47
48
49
50
51
52
53

54
55 *It's time-consuming. It's another thing that a clinician has to do. (Learning session participant*
56 *I-01)*
57

58 Around a third (32.6%) of survey respondents questioned the reliability of the data collected,
59 indicating that they believed that it was 'vulnerable to "gaming" by organisations trying to look
60

1
2
3 *good'* and that the data was not comparable across organisations. One problem was that the NHS
4 Safety Thermometer asked data collectors to record whether the harm was 'old' or 'new' depending
5 on when it occurred. Staff reported that this was a problem because of the way the tool seemed to
6 obscure where and how the harm had occurred and opened up the possibility of blame.
7
8

9
10 *But because it went down on our record, it looked as though it was ours even though it goes*
11 *down as an old or a new, when you put those together it looks as though – oh look, they have*
12 *got pressure ulcers. (Learning session participant I-06)*
13

14
15 Substantial variability was evident in the extent to which organisations used the NHS Safety
16 Thermometer during Safety Express (Figs 1a and 1b). One region did not submit any data. In the first
17 month, only 12 acute organisations submitted data, making 712 patient-level entries. Rates of
18 organisational participation and data submission increased thereafter, with 140 organisations
19 submitting data at least once and an average of 60 organisations contributing data every month
20 throughout the collaborative. A total of 52,309 patient-level line entries were made during Safety
21 Express. A majority (71%) of monthly submissions contained at least 30 patients and 84% achieved
22 at least 20 patients. Data from hospital settings accounted for 90% of all data submitted, with the
23 remainder from non-acute settings including 3% from the patients' own home, 2% from nursing
24 homes and 5% from other settings. Within hospitals, 50% of the settings chosen by participants for
25 testing in hospitals were medical wards.
26
27

28
29 During the second, incentivised data collection phase of the programme, the number of
30 organisations contributing data increased dramatically: 719 organisations used the NHS Safety
31 Thermometer during 2012/13 (146 acute, 573 non-acute). This resulted in a large increase in patient
32 entries into the dataset: 1,882,558 patient entries (Fig. 1b). Diversity in the kinds of organisations
33 contributing data also increased during 2012-13, with particular growth in the proportion of patients
34 from non-acute settings. Of the non-acute, 136 were independent provider sites and 217 were
35 nursing homes. During this period, 58.3% of data were submitted from hospital settings, 7.8% from
36 the patients' own home, 2.3% from nursing homes and 31.6% from other settings.
37
38

39 **Programme Aim 3: Deliver improved outcomes**

40
41 The extent to which the programme met its aim of delivering improved outcomes was difficult to
42 assess, given variability in the number and consistency of organisations submitting data over time.
43 Control chart rules were used to interpret data on harm-free care over the two phases of the
44 programme both in the specific initial Safety Express subgroup of 12 organisations who were the
45 first to join (Fig 3a) and, separately, all organisations (including the initial Safety Express
46 subgroup)(Fig 3b).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The initial Safety Express subgroup organisations all reported data consistently over time. The
4 proportion of harm-free care reported by these organisations rose from 85.1% in January 2011 to
5 89.7% in April 2011 during Safety Express. This increased further to 91.4% by March 2012, and
6 remained stable up to March 2013 (throughout the incentivised data collection phase). (Fig 3a). The
7 proportion of patients who were deemed 'harm-free' in this subgroup did not reach the goal of 95%.
8
9

10
11 In all submitting trusts (including the initial Safety Express subgroup), the proportion of acute
12 patients reported as receiving harm-free care rose from 86.5% January 2011 to 90.2% by July 2011
13 during Safety Express. This increased further to 92.2% in July 2012, and stabilized thereafter, during
14 the incentivised data collection phase (end of March 2013) (Fig. 3b). Again, the 95% aspirational goal
15 was not achieved.
16
17
18
19

20 21 Discussion

22
23 This mixed-method study of a large-scale, two-phase improvement programme using an innovative
24 approach to harm-free care adds to the growing body of evidence on large-scale programmes as a
25 means of securing change in healthcare. We set out to assess the extent to which the harm-free care
26 programme met its aims and the influences on the achievement of those aims. We found that the
27 programme struggled in developing a shared national, regional and locally aligned focus for the
28 harm-free care concept during Phase 1, with policy turbulence a major influence in frustrating goal
29 achievement. The goal of establishing a measurement system for harm-free care was achieved, but
30 in the face of considerable challenge. Whether the third and final goal of improved clinical outcomes
31 was achieved proved difficult to determine. These findings offer valuable learning about the design
32 and conduct of large-scale quality improvement programmes in healthcare. First, this study
33 illustrates the importance of significant upfront investment when launching new data collection
34 tools based on novel concepts, especially when such tools seek to standardise the measures used
35 across diverse settings. Second, it suggests that engagement in voluntary efforts such as quality
36 improvement collaboratives may be contingent on relatively stable organisational and broader
37 institutional contexts: participation and engagement in Safety Express remained patchy throughout
38 its history. It was not until broader structures had settled, and a financial incentive for data
39 collection was introduced in the second phase of the programme, that the reach and consistency of
40 data submission improved. Third, this study illustrates the challenges in interpreting evidence
41 relating to large-scale improvement. There is some indication that the proportion of patients
42 experiencing harm-free care increased over the both phases of the programme, but trends over time
43 in the aggregate submissions must be interpreted cautiously since the same organisations did not
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 submit consistently over time nor did those who were submitting do so consistently, and case-mix
4 varied over time.
5

6
7 One potentially tempting conclusion from this study is that the first phase of the programme was
8 unnecessary since improved consistency of data submission did not occur until the second phase,
9 which financially incentivised data collection. This second phase also saw possible improvements in
10 clinical outcomes, even though little improvement support was available. Such a conclusion might
11 suggest that future efforts to secure improvement should focus primarily on financial incentives,
12 bypassing the messier and more uncertain path of voluntary, collaborative cooperation. But such an
13 argument neglects the important developmental role played by the first phase. Without this, the
14 second phase is likely to have foundered.
15
16
17
18
19

20
21 The developmental role of the first phase was especially critical in developing the NHS Safety
22 Thermometer. Though quality improvement projects are known to be prone to measurement and
23 data collection problems of various kinds, [31, 40, 41] the challenges in developing measures and
24 securing legitimacy are seldom reported. The concepts behind the NHS Safety Thermometer were
25 novel, emphasising a patient-centered approach that required rethinking of traditional metrics and
26 methods of data collection and display. Significant technical and social innovation was required to
27 maximise the chance that the data would be regarded as credible while minimising the risk that data
28 would be too irksome or burdensome to collect.[42] Despite the level of investment and testing,
29 some concerns about consistency, relevance and fairness endured among those submitting data, as
30 has been found elsewhere.[43]
31
32
33
34
35
36

37
38 The first phase of the programme may have been important in developing approaches, definitions
39 and tools, but less clear was the success of the collaborative model in securing change. Though the
40 harm-free care concept was broadly recognised by Safety Express participants as an original and
41 ingenious way to think about patient safety, none of the regions met the engagement metrics;
42 ability to engage was adversely affected by contextual influences, including massive system
43 instability that contributed to distraction, diminished energy, and voids of leadership.[44] It is also
44 likely that the number of participants was too low to achieve the necessary momentum in an area
45 the size of England. Further complicating engagement was the variation that existed between
46 regions and between organisations in their approach to implementation. Better understanding of
47 such variation might have enabled the national programme team to undertake a baseline
48 assessment and co-design a bespoke programme with each locality. These findings affirm earlier
49 evidence[14, 40, 45] indicating that quality improvement collaboratives may have some distinctive
50 strengths but are far from a straightforward solution. It adds to this evidence in demonstrating that
51 the potential of collaboratives may be heavily contingent on their political, economic and social
52
53
54
55
56
57
58
59
60

1
2
3 contexts. Simply put, though they may have advantages over more coercive methods for making
4 change,[46] their success is likely to depend on a supportive outer context. Better understanding of
5 how and when collaboratives are the right approach is an especially important goal given the known
6 risks and limitations associated other means of achieving change, including those associated with
7 use of financial incentives.[47]
8
9

10
11 A limitation of our study is that it was not possible to conduct a process evaluation of the
12 incentivised data collection phase. This means that it is not easy to identify the mechanisms that
13 might have contributed to the possible improvements in proportion of harm-free care that appear to
14 have coincided with the introduction of the data collection requirement. One possibility is that the
15 improvement observed was part of secular trend that was occurring anyway.[48] Another is that the
16 observed improvement is simply an artefact of the data collection process; as data collection
17 expanded, the case-mix became more diverse and included a higher proportion of patients at lower
18 risk of the four harms. A further possibility the introduction of financial incentives encouraged some
19 form of gaming,[49] though there is no direct evidence of this. Finally, it is possible that the observed
20 change was real: that clinical teams did use the NHS Safety Thermometer as intended, recognising
21 the value of a harm-free approach and using the data displays to identify where practice was falling
22 short and making changes. Such an interpretation is consistent with the general observation that
23 data plus feedback can act as an intervention, revealing unwarranted variations in practices, processes
24 and outcomes and helping to inform targets for improvement.[50, 51]
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Limitations of this study include its reliance on clinical outcome data reported to the programme by
39 the participating sites: the data were not independently collected, nor was it possible to engage in
40 verification or validation exercises. We interviewed all those who volunteered and sought
41 disconfirming evidence where possible, but it is possible that those interviewed were primarily
42 those with more positive views, since those participating in the collaborative were, almost by
43 definition, more engaged. The online survey did provide another opportunity to contribute, but it
44 was still vulnerable to capturing the views of the more engaged. It is not clear how generalizable the
45 findings will be to other contexts.
46
47
48
49
50

51 These findings offer important lessons for large-scale improvement programmes. They show that the
52 effort and time required to reach and implement an agreed approach to measurement for
53 improvement, particularly when the measures are novel, should not be underestimated.
54

55 Development of measurement systems requires both cultural change and technical leadership. It is
56 likely that at least six months is needed before an improvement programme starts to allow systems
57 to be optimised. Even then, contestation about data definitions and complaints about data
58
59
60

1
2
3 collection burden may persist and should be anticipated. The collaborative model may have rich
4 potential as a design and developmental phase in large-scale improvement programmes, but may
5 not on its own produce change when external contexts are unfavourable.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Competing interests:

MP, AH and AB were seconded to the Department of Health QIPP programme which ran the projects described in this manuscript. No other authors have a competing interest.

Funding:

The Department of Health Policy Research Programme (Reference No 0770017) funded the research programme of which this evaluation was a part. Analysis of data and write-up of this paper was supported by a Wellcome Trust Senior Investigator award (MDW) WT097899

Ethics committee approval:

NHS Research Ethics Committee approval was obtained for the process evaluation from the Leicestershire, Northamptonshire & Rutland Research Ethics Committee 1 (reference: 10/H0406/38). All personal identifiers have been removed.

Contributorship:

MDW and MP were involved in the study concept and design. SM, JM and PO collected and analysed the qualitative data. GJP, AH and MP analysed the quantitative data. MP, LB, GJP, AB and MDW were involved in the drafting and revised the manuscript. All the authors were involved in the critical revision of the final version of the manuscript.

Acknowledgements:

We thank all of the many organisations and individuals who participated in this research programme for their generosity and support, and our collaborators and the advisory group for the programme. Thanks to Dr Kevin Stewart, (Royal College of Physicians Clinical Effectiveness Unit, London UK) for his clinical leadership throughout the Safety Express programme and Kate Cheema at the South East Coast Quality Observatory for support with design of the NHS Safety thermometer, data collection and analysis. We thank Kasia Noone and Matt Cope for coordinating production of the manuscript.

Data Sharing Statement:

Additional unpublished data are not available.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Baseline assessment	Review 1	Review 2	Review 3	Final review
Safety Express Phase Reviews			Maintenance Phase Review	Incentivized Phase Review
Sept – Dec 2010	April 2011	Sept 2011	Sept 2012	March 2013
<ol style="list-style-type: none"> 1. A named individual in each region to link into the national team, appoint a local team and link into the QIPP team. 2. Identify areas of alignment and discourse between local, regional and national QIPP plans. 3. Recruit ten host organisations and ensure team composition included locality partners. 4. Identify regional faculty for a Safety Express improvement collaborative. 5. Field 100 people at learning session 1 of the collaborative. 	<ol style="list-style-type: none"> 1. Integration of the safe care plans into the regional QIPP plan. 2. Ten teams of ten participating in the collaborative. 3. Participation in fortnightly WebEx meetings (regional leaders) 4. Submission of monthly data using the NHS Safety Thermometer 5. Faculty support, (both 'national' and 'regional' – national included subject matter experts, i.e. in tissue viability / pressure ulcers and nutrition. Regional – leading clinicians and Q.I. experts) to teams between learning sessions (WebEx/site visits/phone calls). 	<ol style="list-style-type: none"> 1. Submission of five case studies of 'innovative practice' to the national team. 2. Submission of monthly data using the NHS Safety Thermometer from each organisation in the collaborative. 3. Well-defined plans for scale up to the remaining organisations in the region, including plans to work collaboratively with commissioners. 4. Identification of teams to put forward for national awards at a Summit event at the end of the pilot. 5. Plans to publish the work. 	<ol style="list-style-type: none"> 1. All organisations in the region to have participated in the CQUIN for collecting NHS ST data monthly. 2. Engagement with Clinical Commissioning Groups to raise awareness of 'harm-free' care programme and the NHS Safety Thermometer CQUIN (e.g. attendance at the Safe Care work stream meeting for commissioners, attendance at CQUIN master classes in which the details of the CQUIN were explained to commissioners from each region). 3. Review regional level data. 4. Publication of the results of the QIPP Safe Care programme of work. 5. Evidence of regional planning for delivery of improvement for the 2013/14 CQUIN. 	<ol style="list-style-type: none"> 1. All organisations participating in the 2013/14 CQUIN to aim to achieve 50% improvement in reduction of the four harms by March 2014. 2. Evidence of the harm-free care programme in Trust's Quality Accounts and/or Trust Board reports. 3. All CCGs commissioning harm-free care locally. 4. All CCGs and organisations to have systems in place to embed 'harm-free' care into contracts and to embed into the new NHS and social care structures. 5. Evidence of support to assist organisations who have not achieved 50% improvement.

1
2
3
4
5 **Table 1:** Safety Express key deliverables and review points for regions, determined in advance
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

Site characteristic	Descriptor	Survey respondents*
Organisation (n=133)	Acute trust	63.9%
	Community trust	24.1%
	Mental health trust	2.3%
	Primary care trust	7.5%
	Strategic Health Authority	6.0%
	Other	4.6%
Staff level banding** (n=134)	Bands 1-4	0.7%
	Bands 5-6	10.4%
	Bands 7-8	61.9%
	Above Band 8	28.4%
	Other	2.1%
Regional cluster (n=134)	North	26.9%
	Midlands/East of England	26.9%
	London	6.7%
	South East Coast	9.7%
	South Central	21.6%
	South West	6.0%
	Prefer not to say	6.0%

Table 2: Survey respondent characteristics

*Some respondents chose more than one option to describe their organisation, banding, and region.

** Most jobs in the NHS are covered by the Agenda for Change (AfC) pay scales. This covers all staff except doctors, dentists and the most senior managers. The AfC job evaluation system determines a point score which is used to match jobs to one of the nine pay bands and determine levels of basic salary (ref: <http://www.nhscareers.nhs.uk/explore-by-career/nursing/pay-for-nurses/>.)

Region	Population ¹ (millions)	Budget ² (in billions)	Collaborative participation			Alignment with workstream goals ⁴					
			Number of host organisations ³ participating in Safety Express	LS1 ⁴ Attendees	LS2 Attendees	LS3 Attendees	Baseline Assessment	Review 1	Review 2	Review 3	Final Review
				(Jan 11)	(Mar 11)	(Jun 11)	(Sep - Dec 10)	(April 11)	(Sep 11)	(Sep 12)	(Mar 13)
1	6.7	£12	15	112	85	72	Amber	Red	Red	Amber	Amber
2	2.5	£4.7	6	31	24	19	Red	Red	Red	Red	Red
3	4.9	£9.3	5	27	25	7	Red	Red	Red	Red	Red
4	4.1	£7.7	10	39	55	32	Amber	Amber	Amber	Red	Red
5	5.3	£5.2	9	87	45	18	Amber	Amber	Red	Red	Red
6	5.4	£10.1	9	22	28	31	Amber	Amber	Green	Green	Green
7	7.4	£13.9	10	75	59	60	Red	Red	Green	Green	Amber
8	4.1	£7.7	22	70	53	43	Amber	Amber	Amber	Amber	Red
9	3.9	£7.3	11	31	22	48	Red	Amber	Red	Red	Red
10	4.9	£9.3	31	81	77	118	Red	Red	Red	Red	Amber

Table 3: Regions’ participation in the collaborative and alignment with programme goals

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

¹ Population in millions rounded to one decimal place; ² Allocation of spend to the nearest £100,000 to each SHA region in FY 2010/11; ³ A host organisation was defined as the lead organisation who collaborated with other organisations across the health economy. ⁴ LS = learning session

For peer review only

1 References

- 1 Landrigan CP, Parry GJ, Bones CB, et al. Temporal trends in rates of patient harm resulting from medical care, *N Engl J Med* 2010;363:2124-34.
- 2 Provenzano A, Rohan S, Trevejo E, et al. Evaluating inpatient mortality: a new electronic review process that gathers information from front-line providers, *BMJ Qual Saf* 2015;24:31-7.
- 3 Hogan H, Healey F, Neale G, et al. Preventable deaths due to problems in care in English acute hospitals: a retrospective case record review study, *BMJ Qual Saf* 2012;21:737-45.
- 4 Berwick DM, Calkins DR, Joseph McCannon C, et al. The 100 000 lives campaign: Setting a goal and a deadline for improving health care quality, *J Am Med Assoc* 2006;295:324-7.
- 5 Benning A, Ghaleb M, Suokas A, et al. Large scale organisational intervention to improve patient safety in four UK hospitals: mixed method evaluation, *BMJ* 2011;342:d195 doi:10.1136/bmj.d195 [published Online First: Feb 3].
- 6 Benning A, Dixon-Woods M, Nwulu U, et al. Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase, *BMJ* 2011;342:d195-.
- 7 Krumholz HM, Bradley EH, Nallamothu BK, et al. A Campaign to Improve the Timeliness of Primary Percutaneous Coronary Intervention: Door-to-Balloon: An Alliance for Quality, *J Am Coll Cardiol Intv* 2008;1:97-104.
- 8 Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study, *The Lancet infectious diseases* 2012.
- 9 Bion J, Richardson A, Hibbert P, et al. 'Matching Michigan': a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England, *BMJ Qual Saf* 2012.
- 10 Forster AJ, Worthington JR, Hawken S, et al. Using prospective clinical surveillance to identify adverse events in hospital, *BMJ Quality & Safety* 2011;20:756-63.
- 11 Lecko C. Patient safety and nutrition and hydration in the elderly. 2013.
- 12 Morris-Thompson T, Aldred V, Clark N, et al. Safety Express: a strategic health authority's approach, *British journal of nursing* 2012;21:677-83.
- 13 Health and Social Care Information Centre. NHS Safety Thermometer. 2013;2016.

- 1
2
3 14 Hulscher ME, Schouten LM, Grol RP, et al. Determinants of success of quality improvement
4 collaboratives: what does the literature show? *BMJ Quality & Safety* 2012.
5
6
7 15 Dixon-Woods M, Bosk CL, Aveling EL, et al. Explaining Michigan: developing an ex post theory of a
8 quality improvement program, *Milbank Q* 2011;89:167-205.
9
10 16 Institute for Healthcare Improvement. The Breakthrough Series: IHI's Collaborative Model for
11 Achieving Breakthrough Improvement. IHI Innovation Series white paper. *Boston: Institute for*
12 *Healthcare Improvement* 2003.
13
14 17 Ozieranski P, Robins V, Minion J, et al. Running a hospital patient safety campaign: a qualitative
15 study, *Journal of Health Organization and Management* 2014;28:562-75.
16
17
18 18 Pronovost PJ, Goeschel CA, Marsteller JA, et al. Framework for patient safety research and
19 improvement, *Circulation* 2009;119:330-7.
20
21
22 19 Dixon-Woods M, McNicol S, Martin GP. Ten challenges in improving quality in health care: lessons
23 from the Health Foundation's programme evaluations and relevant literature, *BMJ Quality & Safety*
24 2012;21:876-84.
25
26
27 20 Aveling EL, Martin G, Armstrong N, et al. Quality improvement through clinical communities:
28 eight lessons for practice, *J of Health Org and Mgt* 2012;26:158-74.
29
30
31 21 Soo S, Berta W, Baker GR. Role of champions in the implementation of patient safety practice
32 change, *Healthc Q* 2009;12:123-8.
33
34
35 22 Fuller C, Michie S, Savage J, et al. The Feedback Intervention Trial (FIT) - Improving Hand-Hygiene
36 Compliance in UK Healthcare Workers: A Stepped Wedge Cluster Randomised Controlled Trial, *PLoS*
37 *ONE* 2012;7.
38
39
40 23 Dixon-Woods M, McNicol S, Martin G. Ten challenges in improving quality in healthcare: lessons
41 from the Health Foundation's programme evaluations and relevant literature, *BMJ Quality Safety*
42 2012;21:876-84.
43
44
45 24 Cronshaw HL, Daniels R, Bleetman A, et al. Impact of the Surviving Sepsis Campaign on the
46 recognition and management of severe sepsis in the emergency department: are we failing? *Emerg*
47 *Med J* 2011;28:670-5.
48
49
50 25 Power M, Tyrrell PJ, Rudd AG, et al. Did a quality improvement collaborative make stroke care
51 better? A cluster randomized trial, *Implementation Science* 2014;9:40-.
52
53
54 26 Hawe P. Lessons from complex interventions to improve health, *Annu Rev Public Health*
55 2015;36:307-23.
56
57
58 27 Dixon-Woods M. The problem of context in quality improvement. 2014.
59
60

- 1
2
3 28 Datta J, Petticrew M. Challenges to evaluating complex interventions: a content analysis of
4 published papers, *BMC Public Health* 2013;13:1.
5
6
7 29 Pronovost PJ, Lilford R. Analysis & commentary: A road map for improving the performance of
8 performance measures, *Health Aff (Millwood)* 2011;30:569-73.
9
10 30 Marshall M, Pronovost P, Dixon-Woods M. Promotion of improvement as a science, *Lancet*
11 2013;381:419-21.
12
13
14 31 Benn J, Burnett S, Parand A, et al. Studying large-scale programmes to improve patient safety in
15 whole care systems: Challenges for research, *Soc Sci Med* 2009;69:1767-76.
16
17
18 32 Portela MC, Pronovost PJ, Woodcock T, et al. How to study improvement interventions: a brief
19 overview of possible study types, *BMJ Qual Saf* 2015;24:325-36.
20
21
22 33 Dixon-Woods M, Baker M, Charles J, et al. Culture and behaviour in the English National Health
23 Services: overview of lessons from a large multi-method study, *BMJ Qual Saf* 2013;23:106-15.
24
25
26 34 Creswell, John W., Plano Clark, Vicki L., Designing and conducting mixed methods research. Los
27 Angeles: SAGE Publications 2011.
28
29
30 35 Dixon-Woods M, Agarwal S, Jones D, et al. Synthesising qualitative and quantitative evidence: A
31 review of possible methods, *Journal of Health Services Research and Policy* 2005;10:45-53.
32
33
34 36 Charmaz K. Constructing grounded theory: A practical guide through qualitative analysis. London:
35 Sage 2006.
36
37
38 37 Glaser B, Strauss A. The discovery of grounded theory. Hawthorne, NY: Aldine Publishing
39 Company 1967.
40
41
42 38 Altheide DL. Ethnographic content analysis. In: Lewis Beck MS, Bryman A, Liao TF, eds. The Sage
43 Encyclopaedia of Social Science Research Methods. Thousand Oaks, Ca: Sage 2004.
44
45
46 39 Power M, Fogarty M, Madsen J, et al. Learning from the design and development of the NHS
47 Safety Thermometer, *Int J Qual Health Care* 2014;26:287-97.
48
49
50 40 Schouten LM, Hulscher ME, van Everdingen JJ, et al. Evidence for the impact of quality
51 improvement collaboratives: systematic review, *BMJ* 2008;336:1491-4.
52
53
54 41 Needham DM, Sinopoli DJ, Dinglas VD, et al. Improving data quality control in quality
55 improvement projects, *Int J Qual Health Care* 2009;21:145-50.
56
57
58 42 Pronovost PJ, Nolan T, Zeger S, et al. How can clinicians measure safety and quality in acute care?
59 *Lancet* 2004;363:1061-7.
60

1
2
3 43 Dixon-Woods M, Leslie M, Tarrant C, et al. Explaining Matching Michigan: an ethnographic study
4 of a patient safety program, *Implement Sci* 2013;8:70.

5
6
7 44 McKee L, Charles K, Dixon-Woods M, et al. New” and distributed leadership in quality and safety
8 in healthcare, or “old” and hierarchical? An interview study with strategic stakeholders *Journal of*
9 *Health Services Research and Policy* 2013;DOI: 10.1177/1355819613484460.

10
11
12 45 Øvretveit J, Bate P, Cleary P, et al. Quality collaboratives: lessons from research, *Quality and*
13 *safety in health care* 2002;11:345-51.

14
15
16 46 Martin G, Armstrong N, Dixon-Woods M, et al. Professionalism Redundant, Reshaped, or
17 Reinvigorated? Realizing the ‘Third Logic’ in Contemporary Healthcare, *Journal of Health and Social*
18 *Behaviour* 2015;Published online before print.

19
20
21 47 Roland M, Dudley RA. How Financial and Reputational Incentives Can Be Used to Improve
22 Medical Care, *Health Serv Res* 2015;50:2090-115.

23
24
25 48 Chen YF, Hemming K, Stevens AJ, et al. Secular trends and evaluation of complex interventions:
26 the rising tide phenomenon, *BMJ Qual Saf* 2016;25:303-10.

27
28
29 49 Bevan G, Hood C. What's measured is what matters: Targets and gaming in the English public
30 health care system, *Public Administration* 2006;84:517-38.

31
32
33 50 Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and
34 healthcare outcomes. *Cochrane database of systematic reviews (Online)* 2012;6.

35
36
37 51 Brown JR, Solomon RJ, Sarnak MJ, et al. Reducing Contrast-Induced Acute Kidney Injury Using a
38 Regional Multicenter Quality Improvement Intervention. *Circulation: Cardiovascular Quality and*
39 *Outcomes* 2014.




Figure 1a: Number of organisations submitting data over time*
 *NHS Trusts submitting NHS Safety Thermometer data over time, from the start of the Safety Express programme ('Phase 1') through to end of the first period of incentivised data collection ('Phase 2'). Bar height represents the total unique NHS Trusts submitting within the month. In January 2011, 12 organisations submitted. In March 2013, this had risen to 252 organisations.

1a
 73x50mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1b: Number of patient entries submitted over time.*

*Number of individual patient-level entries submitted to the NHS Safety Thermometer over time from the start of the Safety Express programme ('Phase 1') through to end of the first period of incentivised data collection ('Phase 2'). Bar height represents the total patients submitted within the month. In January 2011, 712 patients were surveyed and their data submitted against the 'harm-free' Care measure. In March 2013, this was 98,372 patients.

1b
70x49mm (300 x 300 DPI)




Figure 2: Timeline of key political and policy events 2009-2012

Fig. 2
77x51mm (300 x 300 DPI)




Figure 3a: Percent harm-free care over time for patient entries submitted from the initial Safety Express ('Phase 1') cohort in January 2011 over time, until the end of the incentivised data collection period ('Phase 2') plotted as a P prime chart*

*P' Chart showing percent of patients from the initial cohort of Safety Express ('Phase 1') organisations experiencing harm-free care as defined by the NHS Safety Thermometer, presented over time. These data are plotted as a P prime (P') chart; a type of control chart used for time-series data with a large denominator. Individual data points represent the % of patients in the cohort who received harm-free care each month; in January 2011 this was 85.1%. In March 2013, this was 91.4%. Control limits are used to apply control chart rules to detect special cause. The original plot of these data highlighted three distinct phases, indicated by the readjusted mean line.

3a
60x33mm (300 x 300 DPI)




Figure 3b: Percent harm-free care over time for patient entries from all submitting acute care trusts over time, from the beginning of the 'Safety Express' period ('Phase 1') to the end of the incentivised data collection period ('Phase 2') plotted as a P prime chart*

*P' Chart showing percent of patients experiencing harm-free care (as defined by the NHS Safety Thermometer) whilst an inpatient in an acute bed, at any submitting NHS Trust, presented over time. Similar to Figure 3a, these data are plotted as a P prime (P') chart. Individual data points represent the % of patients who received harm-free care each month; in January 2011 this was 86.5%. In March 2013, this was 92.2%. Control limits are used to apply control chart rules to detect special cause. The original plot of these data highlighted three distinct phases, indicated by the readjusted mean line.

3b
60x33mm (300 x 300 DPI)

BMJ Open

A multi-method study of a large-scale programme to improve patient safety using a harm-free care approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011886.R2
Article Type:	Research
Date Submitted by the Author:	07-Jul-2016
Complete List of Authors:	Power, Maxine; Salford Royal NHS Foundation Trust, HAELO Brewster, Elizabeth; University of Lancaster, Medical Education Parry, Gareth; Harvard Medical School, Brotherton, Ailsa; Salford Royal NHS Foundation Trust, HAELO Minion, Joel; University of Bristol, Social Medicine Ozieranski, Piotr; University of Bath McNicol, Sarah; Manchester Metropolitan University Department of Exercise and Sport Science Harrison, Abigail; Salford Royal NHS Foundation Trust, Haelo DixonWoods, Mary; University of Leicester, Health Sciences
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health policy
Keywords:	patient safety, measurement, improvement programmes, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, quality improvement collaboratives, mixed-methods

SCHOLARONE™
Manuscripts

only

A multi-method study of a large-scale programme to improve patient safety using a harm-free care approach

AUTHORS

Maxine Power¹

Liz Brewster²

Gareth Parry³

Ailsa Brotherton¹

Joel Minion⁴

Piotr Ozieranski⁵

Sarah McNicol⁶

Abigail Harrison¹

Mary Dixon-Woods^{7*}

¹Haelo, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK

²Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YW, UK

³Institute for Healthcare Improvement, 20 University Rd, Cambridge, MA 02138, United States

⁴Data to Knowledge Group, School of Social and Community Medicine, University of Bristol, Bristol BS8 2BN, UK

⁵Department of Social and Policy Sciences, University of Bath, Bath, BA2 7AY, UK

⁶Education and Social Research Institute, Manchester Metropolitan University, Crewe Green Road, Crewe, Cheshire, CW1 5DU

⁷Cambridge Centre for Health Services Research, University of Cambridge School of Clinical Medicine, Box 113 Cambridge Biomedical Campus, Cambridge CB2 0SR

*Corresponding author. *Rand Professor of Health Services Research, Institute of Public Health*

Forvie Site, University of Cambridge School of Clinical Medicine, Box 113 Cambridge Biomedical Campus, Cambridge CB2 0SR. Tel: + 44 116 2297262 email: md753@medschl.cam.ac.uk

Keywords: Quality improvement collaboratives; Quality Improvement, Implementation, Patient Safety, National Health Service

Abstract

Objectives: We aimed to evaluate whether a large-scale two-phase quality improvement programme achieved its aims and to characterise the influences on achievement.

Setting: National Health Service (NHS) in England.

Participants: NHS staff.

Interventions: The programme sought to: 1) develop a shared national, regional and locally aligned safety focus for four high-cost, high volume harms; 2) establish a new measurement system based on a composite measure of “harm-free” care; 3) deliver improved outcomes. Phase 1 involved a quality improvement collaborative intended to involve 100 organisations; phase 2 used financial incentives for data collection.

Measures: Multi-method evaluation of the programme. In Phase 1, analysis of regional plans and of rates of data submission and clinical outcomes reported to the programme. A concurrent process evaluation was conducted of Phase 1, but only data on submission rates and clinical outcomes were available for Phase 2.

Results: A context of extreme policy-related structural turbulence impacted strongly on Phase 1. Most regions’ plans did not demonstrate full alignment with the national programme; most fell short of recruitment targets and attrition in attendance at the collaborative meetings occurred over time. Though collaborative participants saw the principles underlying the programme as attractive, useful and innovative, they often struggled to convert enthusiasm into change. Developing the measurement system was arduous, yet continued to be met by controversy. Data submission rates remained patchy throughout Phase 1 but improved in reach and consistency in Phase 2 in response to financial incentives. Some evidence of improvement in clinical outcomes over time could be detected but was hard to interpret owing to variability in the denominators.

Conclusions: These findings offer important lessons for large-scale improvement programmes, particularly when they seek to develop novel concepts and measures. External contexts may exert far-reaching influence. The challenges of developing measurement systems should not be underestimated.

Strengths

- The multi--method design enabled a holistic evaluation.
- The study reveals the impact of policy and structural turbulence on ability to achieve change in health systems.
- The importance of a rigorous development phase for improvement programmes, including significant investment upfront in measurement and data systems, was identified.

Weaknesses

- The process evaluation of the first phase of the programme may have been biased towards those with more positive views.
- The absence of a process evaluation for the second phase of the programme is a further limitation.
- Independent data on clinical outcomes were not available, and the evaluation thus relied on data collected by the programme itself.

Introduction

How best to ensure the safety of patients continues to challenge health systems worldwide.[1-3] Recent years have seen multiple efforts to secure improvements. Some have multiple safety targets and seek generalised strengthening of organisational systems, processes and cultures,[4-6] while others target specific areas of harm or practice.[7-9] Whatever their form, improvement programmes typically measure outcomes one by one, with incidence for each – for example central venous catheter bloodstream infections or unplanned readmissions to hospital - reported singly and separately, rather than in terms of how many harms each person suffered. Most also focus on specific, well-bounded healthcare settings and measure harms that are assumed to be attributable to the care provided in those environments.

Some (though not all) patient safety programmes have reported welcome successes in relation to specific harms. From the patient's perspective, however, a focus on single outcomes in well-bounded healthcare settings may be deficient, potentially obscuring individuals' experiences across pathways of care and their exposure to concatenations of multiple adverse events.[10] Addressing harms singly also has other unintended consequences, including the reinforcement of disciplinary boundaries. Infection control nurses may, for example, work in isolation from tissue viability nurses with the same patients. Thus, a potentially more useful approach to safety might focus on the extent to which patients escape all possible harms and could thus be deemed to have experienced care that is "harm-free". In this article, we report a study of a large-scale programme seeking to promote an innovative approach to harm-free care in England.

The harm-free care programme

Run as part of the Department of Health's Quality, Innovation, Productivity and Prevention (QIPP) 'Safe Care' workstream,[11] the programme was led by a dedicated national programme team and had three major goals:

- Develop a shared national, regional and locally aligned safety focus for four high-cost, high volume harms (venous thrombo-embolism (VTE), pressure ulcers, urinary tract infection in patients with urinary catheters, and falls). These four harms were selected because they account for a large proportion of all avoidable injury to patients and share many underlying factors (e.g. mobility, medication management, nutrition, hydration) relating to basic patient care, yet may involve trade-offs in managing risk;[1, 12]
- Establish a measurement system based on the principle that a new patient-centred measure that would "bundle" harms into a single, composite score of harm-free care would bring new

insights into harm rates, enable clinical teams to identify and recognise where problems lay, and motivate local improvement;

- Deliver improved clinical outcomes, with a specific objective of ensuring that 95% of patients would be harm-free.

The programme did not seek to develop new technical interventions for managing the four harms nor to set targets, but instead sought: to ensure that addressing the four harms together for each patient was identified as a priority for organisations, to support organisations and teams in implementing existing good practice in relation to the four harms, and to provide a well-founded means of surveillance, monitoring and feedback on harm-free care. It ran in two distinct phases. The first phase ran September 2010 to April 2012, including a three-month preparatory period at the beginning (September 2010-December 2010) and a six-month maintenance period at the end (October 2011-April 2012). This first phase sought to pilot an approach to measuring and improving patient safety, to support a cohort of organisations to implement and test it, and ultimately to prepare the way for the subsequent use of the approach across all care settings in England. To achieve these aspirations, the national team undertook an intensive period of programme design, refinement of operational definitions, cycles of testing and learning, and developing and modifying a data collection tool for harm-free care.

This tool, which came to be known as the NHS Safety Thermometer, sought to enable collection of data that would both be comparable at a national level and useful in local improvement work,[13] and that would balance accurate measurement and standardised definitions with straightforward data collection methods that did not burden staff. The design period was followed by work to implement the programme through regional and local partnerships (Table 1), much of it organised through a voluntary quality improvement collaborative known as Safety Express.

Use of the collaborative model[14] was based on the theory that it would facilitate rapid shared learning and the mobilisation of collective cross-multidisciplinary action.[15] Consistent with the BreakThrough Series collaborative approach,[16] Safety Express involved three learning events where participants across the regions came together and action periods during which participants were asked to implement improvement activities (e.g. setting up data collection systems and implementing Plan-Do-Study-Act cycles). Participants were recruited through the 10 Strategic Health Authority (SHA) regions then extant in the English NHS. Each region was asked to engage 10 participating organisations serving a local population, and each of these organisations was asked to ensure that 10 staff members (primarily front-line clinicians) attended the learning events and that they tested the NHS Safety Thermometer in a relevant caseload. The work of clinical teams in undertaking these activities was supported by the regional and national teams, as well as by online

resources and detailed guidance on good practice interventions and on how to submit and interpret local data. Participating organisations were asked to collect data on four wards (acute) or on their caseloads (non-acute) on one day per month using the NHS Safety Thermometer and to submit it to a central data collection facility. A six-month maintenance period during which organisations were asked to continue submitting data followed the completion of Safety Express in September 2011. Some support, albeit limited, was available to organisations on request during the maintenance period.

The second phase of the programme ran April 2012 to March 2013, when it expanded beyond the original participants to include all settings providing care for NHS patients in England. An important characteristic of this phase is that financial incentives were offered to all NHS organisations in England to submit data on 100% of patients on one day per month using the NHS Safety Thermometer. Only limited improvement support was available: the collaborative did not continue, though access to online resources remained, and some limited support was available from the NHS Institute for Improvement and Innovation up to March 2013. Some locally organised (not nationally coordinated) support activity also took place.

Study aim

The available evidence suggests that large-scale programmes may offer some important advantages over single-organisation efforts[17] by supporting the infrastructure for improvement, including the development of well-founded interventions and data systems[18] as well as activating the social conditions, peer-norming effects and shared learning most likely to foster change[15, 19, 20] and enabling change at scale. A growing body of evidence now points to the features essential to the success of such programmes, including shared goals among participants, clinician engagement, clinical champions, and the importance of well-designed, theoretically sound interventions[5, 21-23]. However, large-scale improvement programmes continue to show a mixed picture of success, with many reporting disappointingly modest (or no) improvements in implementation of evidence-based interventions in practice.[24, 25] These findings suggest that much remains to be learned about these complex interventions,[26] for example regarding contextual influences,[27] programme design and implementation,[28] measurement,[29, 30] and sustainability beyond project timelines.[31]

With the aim of addressing these gaps in knowledge and improving the evidence-base for future large-scale improvement programmes, particularly when they involve novel approaches and measures, our study sought to assess how far the harm-free programme met its three aims and to identify and characterise the influences on the achievement of these aims.

Methods

We conducted a multi-method evaluation “wrapped around” the programme,[32] rather than a research study that set out to test specific hypotheses. During Phase 1 of the programme, we used a combination of data collected by the programme itself and an independent process evaluation. The programme data included an analysis conducted by the national team of the extent to which regional strategy was aligned to national goals, information on the number of organisations that were submitting data on the four harms, and the data on clinical outcomes (the four harms) submitted by participating organisations. As part of a wider study of quality and safety in the NHS,[33] we also conducted a concurrent process evaluation of Safety Express (the quality improvement collaborative that ran during Phase 1), using interview, observational, questionnaire and documentary data. The process evaluation was used as part of a convergent design directed towards obtaining different but complementary data and thus developing a more complete understanding of the programme at multiple levels.[34] Approval for the process evaluation was obtained from an NHS REC. Signed consent was obtained for interviews.

For reasons of resource, only the programme data on submission rates and clinical outcomes submitted by the participating organisations were available for Phase 2. The organisations submitting data changed over time (especially between Phase 1 and Phase 2), leading to denominators that increased in size and diversity over time. Twelve organisations submitted data consistently from January 2011 to March 2013, and these were subject to sub-group analysis.

All quantitative data were collected and analysed by the programme team; all qualitative data were collected and analysed by an evaluation team independent of programme team (Boxes 1 and 2). The data were analysed separately and then synthesised thematically.[35]

Box 1: Quantitative data

Programme goal	Data	Analysis
Develop a shared national, regional and locally aligned safety focus , assessed through inclusion of the four harms in each region’s system-level strategy plans and QIPP improvement programmes.	Each region’s progress extracted from plans and mapped on four occasions using a categorical rating scale, used to assess achievement of programme goal of a shared national, regional and locally aligned safety focus for the four harms.	A judgment was made by the programme team to determine whether the region was achieving four or more of the milestones (green), two to three (amber) or one or less (red).
Develop a shared, national, regional and locally aligned safety focus : participation in the collaborative, delivery of the required programme	The number of participating organisations and the number of attendees each region sent to each learning session in Safety Express was recorded,	Count data displayed as descriptive statistics and percentages.

outputs and NHS Safety Thermometer data collection.	used to assess achievement of goal of a shared national, regional and locally aligned safety focus for the four harms.	
Establish a measurement system , assessed by tracking number of sites submitting data over time.	Number of organisations submitting data on the four harms.	Description.
Deliver improved clinical outcomes , assessed by determining absence of all four harms at the individual patient level	<p>For each patient, data were collected by local clinicians on four outcomes (pressure ulcers, falls, urinary tract infection in patients with urinary catheters, and VTE) and submitted using the NHS Safety Thermometer, used to monitor progress towards the programme of improved clinical outcomes.</p> <p>To allow for variation in organisations submitting data over time, two cohorts were formed:</p> <p>1) Data from acute patients from the initial, Phase 1 Safety Express organisations consistently submitting between January 2011 and March 2013</p> <p>2) Data from acute patients from all organisations submitting at any time between January 2011 and March 2013.</p>	<p>The composite measure of harm-free care was plotted over time using a control chart. To take account of over-dispersion, due to the large sample size, a P' control chart was used. Standard control chart rules were applied to indicate special and common cause variation and when a shift in the average occurred. Statistical analysis was performed using R-2.15.1 for Windows (http://cran.r-project.org/bin/windows/base/old/2.15.1/).</p>

Box 2: Process Evaluation (Phase 1 only)

Method	Data	Analysis
<p>Semi-structured interviews. A prompt guide was used to elicit experiences and views of the programme from stakeholders who were purposively sampled to represent different constituencies (e.g national, regional and local). Participants were recruited through email coordinated by the national team. Theoretical sampling was not possible due to the nature of recruitment; instead all those who agreed to be interviewed over a defined time-frame were interviewed. It was not possible to assess theoretical saturation formally. Interviews were audio-recorded and transcribed.</p>	<p>Interviews with seven QIPP national team members, six local coordination leads and 11 programme participants. The local programme co-ordination leads were more senior nursing staff, located in four of the 10 Strategic Health Authorities. The programme participants interviewed were mainly nursing staff with responsibility for clinical governance, tissue viability, or patient safety and were based in eight of the 10 regions. These data were used to assess influences on the programme's achievement of its goals of shared goals and establishment of a measurement system.</p>	<p>Analysis was based on the constant comparative method, facilitated by NVivo software[36, 37]. Open codes were generated through close reading of transcriptions. Reflection and interpretation was used to produce a higher level of abstraction and thematic categories. Coding of transcripts was supported by NVIVO 8 software.</p>
<p>Observations. Observers took detailed field notes and held debrief sessions, which were audio-recorded and transcribed.</p>	<p>Ethnographic observations to assess the experience of participating in the programme were conducted at Six Safety Express learning events.</p>	<p>As above</p>
<p>Survey. Based on the observational and interview data, an online survey was developed and circulated to all learning event participants and through email contact channels. Covering implementation of the programme, data measurement and organisational involvement, the majority of the 40 survey questions were multiple-choice or Likert scale, with four free-text questions used to elicit more in-depth responses.</p>	<p>The survey received 157 anonymised responses; because of the method of email distribution, it was not possible to calculate a response rate. A diverse selection of respondents completed the survey (Table 2), reflecting those participating in the project. These data were used to assess influences on the programme's achievement of its goals.</p>	<p>Descriptive analyses of the survey data, with free-text responses coded using content analysis.[38]</p>
<p>Documents. Project documentation and key policy documents were purposively sampled.</p>	<p>~20 relevant documents, including policy materials, were collected from the programme team and from QIPP and other websites. These were used to gather information about the programme and possible contextual influences.</p>	<p>Review and summary.</p>

Results

The process evaluation, which focused on Phase 1 only, involved 24 interviews, 157 survey responses, 48 hours of observation, and around 20 documents. Data on clinical outcomes were submitted by participating organisations over both phases on the programme, though the composition of the contributing organisations and the consistency with which individual

1
2
3 organisations submitted data varied over time (Figs 1a and 1b). Quotations are numbered to indicate
4 different participants and preserve anonymity.
5
6
7
8

9
10 **Achievement of programme aim 1: Develop a shared national, regional and locally aligned safety**
11 **focus for the four harms**

12
13 Evidence on the development of a shared national, regional and locally aligned safety focus for the
14 four harms during Phase 1 was assessed through an analysis of the plans that regions submitted to
15 the national programme team. A mixed picture emerged. Substantial variability (Table 1) was
16 evident in how well the regions' plans were aligned with those of the national programme. Only two
17 of the ten regions' plans were rated as 'green' on the rating scale by September 2011 (almost nine
18 months after the start of the programme) and only one organisation maintained this for over a year
19 (Table 3).
20
21
22
23
24

25
26 All 10 regions signed up to participate in the Safety Express collaborative, but only two were able to
27 reach the goal they were set of recruiting 10 participating organisations. Instead, regions recruited
28 between five and 31 organisations. No site was able to consistently provide 100 participants at each
29 learning event (the numbers attending ranged from 22 to 118), meaning that the goal of enrolling
30 1000 front-line clinicians was not reached. In seven regions, attrition occurred in the number of
31 delegates attending the learning events as the programme progressed.
32
33
34
35

36
37 Interviews showed that many (though not all) participants saw the principles underlying the
38 programme as attractive, useful and innovative. Much support was expressed for the programme
39 principle of taking a holistic approach to harm: almost two-thirds (64%) of survey participants
40 strongly agreed or agreed that the four harms chosen were the most important for their
41 organisation to address, and interview participants were also generally positive about the approach
42 to harm-free care. Survey and interview data suggested that participants generally valued the
43 collaborative features of the programme, with the learning sessions and encouragement from the
44 national team seen as particularly useful. Observations at the Safety Express learning sessions found
45 that participants demonstrated considerable enthusiasm, and that the sessions helped to build
46 relationships and share learning, ideas and practical tools.
47
48
49
50
51
52

53 *I mean we could bounce ideas off them, say we have thought about this, is anybody else*
54 *doing something similar who we can talk to? So they have got that information to signpost*
55 *us. (Learning session participant I-05)*
56
57

58 However, the ambition of the programme daunted some participants. Just under half (44.6%) of
59 survey respondents reported that the programme was greeted with 'initiative fatigue' in their
60

1
2
3 organisation. Though nearly three-quarters (73.2%) reported that achieving 'harm-free' care was a
4 realistic goal for the NHS, just over a third (34.8%) thought their organisation was close to attaining
5 it. Translating the enthusiasm generated by collaborative activities into local action remained a
6 challenge for many.
7
8

9
10 *The ethos of it is obviously just what it should be, but how achievable it is I am not sure.*
11 *(Learning session participant I-06)*

12
13 *Brilliant for networking and we all left feeling positive [...] it was the sustainability following*
14 *the events [that was] difficult. Because obviously you leave the room full of ideas and you go*
15 *back to your everyday work and... it's very difficult to keep it going, I have to say. (Learning*
16 *session participant)*
17
18

19 The most profound influence on the ability of regions and organisations to engage with the
20 programme appeared to be the context of extreme policy turbulence and structural change.
21 Documentary analysis of the 2009-12 policy context (Fig. 2) identified the transformations of the
22 NHS architecture associated with the Health and Social Care Act (2012), with the effects evident
23 both before (in anticipation of) and after the passing of the legislation. Alongside many changes, a
24 new national commissioning board was created (NHS England) and the 10 Strategic Health
25 Authorities were replaced by four regional offices of NHS England. The national bodies that had
26 supported system change were decommissioned (the NHS Institute in March 2013 and the National
27 Patient Safety Agency in June 2012). Loss of senior leadership at the national and regional level
28 contributed to voids of coordination and communication during the programme. Interviews with the
29 programme showed that in all but one region, the problems faced in delivering the programme
30 caused by external and internal turbulence necessitated implementation of a recovery plan and the
31 establishment of direct communication between the national team and the participating teams
32 rather than through the regions.
33
34
35
36
37
38
39
40
41
42

43 **Achievement of programme aim 2: Establish a measurement system to understand the burden of** 44 **the four harms**

45
46 The programme largely succeeded in its aim of establishing a measurement system, but interviews
47 and observations showed that the process of its development was effortful and it continued to
48 generate considerable controversy throughout the programme.
49
50

51
52 Interviews, documents and observations found that a prototype of the NHS Safety Thermometer
53 data collection tool was developed by the national programme team during the design period of
54 Phase 1, and refined iteratively thereafter. Intended to be used by frontline staff, who were asked to
55 collect data on the four harms by reviewing patients' records and examining and speaking to the
56 patient harms,[39]the tool enabled entry of data through an online spreadsheet. It provided instant
57
58
59
60

1
2
3 data display for the participating clinical teams, and, through a merge function, supported
4 aggregation to give whole organisational, regional and national datasets. Though rates of each of the
5 four harms could be viewed separately, a novel feature of the NHS Safety Thermometer was its
6 ability to generate a composite measure of “harm-free” care to indicate the proportion of patients
7 who had not experienced any of the four harms.
8
9

10
11 During Safety Express, the 10 regions were asked to coordinate collection of data using the NHS
12 Safety Thermometer from ten organisations from their region. Each of these 10 organisations was
13 asked to collect data and submit on four wards (acute) or caseloads (non-acute) on one day per
14 month. In interviews, many Safety Express participants saw the NHS Safety Thermometer as
15 innovative, providing a useful and valuable dataset that could be used to drive improvements and
16 provide evidence of progress. They reported that the tool had several advantages in comparison
17 with some available methods of measurement, including the potential that the tool provided for
18 intervening and improving care on the spot. Some participants reported that working across all four
19 harms helped to avoid duplication, both of data collection and effort.
20
21
22
23
24
25

26
27 *The sheer number of nurses that have said: what is fabulous about it is that it means that I*
28 *can improve patient care while the patient is right here, still in the bed and still when I can do*
29 *something about it [...] When I did the Safety Thermometer it was clear the [patient] had not*
30 *had a VTE assessment done so I got the junior doctor to do it for them. (National team*
31 *member I-22)*
32
33

34 *My understanding was that [the harms] selected themselves really because they were the*
35 *biggest category of avoidable harms in healthcare and from that point of view I think they*
36 *were the right ones to focus on. (Local organiser I-05)*
37
38

39 Some participants (including around 20% of survey respondents) commented on the value of having
40 shared definitions and being able to collect comparable data on harms across organisations.
41
42

43 *The consistent approach across the country so we measure apples and apples. [Survey]*
44

45 *[NHS Safety Thermometer] is the first time that we have actually been nationally able to*
46 *measure something in the same way to the same definition... I don't think that has happened*
47 *in anywhere in Europe. (Local organiser I-15)*
48

49 However, developing and deploying the NHS Safety Thermometer was not without substantial
50 challenges. The time required to develop the tool was lengthy, much greater than the programme
51 team had initially anticipated; modifications were still being made to the data collection instrument
52 late in 2011, almost eleven months after the start of the collaborative. Questions and disagreement
53 about the inclusion of the harms and their exact definition dogged the development of the
54 programme, in particular, as shown by observations and interviews, by introducing delays while
55 consensus was sought. This was particularly true of the inclusion of the measure relating to urinary
56
57
58
59
60

tract infection in patients with urinary catheters, which some participants disputed or reported was unclear. Over one in 10 (11.8%) of survey respondents felt that the inclusion of this measure in the programme was not soundly based in scientific evidence, compared with just 2% feeling that there was no scientific basis to include VTE.

I think the other thing with falls and pressure ulcers is that there are quite clear definitions that everyone agrees on. For catheter associated UTIs it has not been the same... That has created quite a lot of confusion. [Local organiser I-15]

Because of some of the questions around the measurement piece, because of the questions around – well what does the definition for UTI look like in my organisation compared to yours? Very valid conversations but nonetheless quite stalling [National team member I-18]

Some participants, for example in the sessions we observed as well as in interviews, expressed a very strong view that a national measurement strategy was neither useful nor appropriate. Organisations and individuals were often already using their own local definitions of some or all of the four harms, and had established methods of data collection and data display (though these were largely from incident reporting systems). Participants did not always demonstrate consensus that the four harms chosen by the programme were the most important focus for improvement efforts in their own organisations.

The difficulty with it is that if we've already got a system and a process in place in some organisations to measure what they're doing against falls, pressure ulcers, whatever, individually, the link hasn't been there. (Local organiser I-24)

The number of updates to the tool over the course of Safety Express in response to feedback caused some frustration among participants, who did not always appreciate the developmental nature of the first phase of the programme. Participants also complained, in interviews and in the survey, that the tool was not as easy to use as intended. The extent to which data collection would need to be supported was initially under-estimated by the national team; some months in, they reported that it became clear that there was a skills gap in relation to measurement in many participants, who were often inexperienced in collecting or using data for improvement. Documents and interviews showed that the produced a suite of materials to support learning and implementation and delivered a series of learning workshops across the country on measuring improvement, including technical capability (actual use of the data tool). In the survey, half (50.0%) of respondents described the tool as 'straightforward,' but nearly half (44.3%) felt that data collection was a major burden. Some teams struggled to integrate the new data collection into their existing practice.

It's time-consuming. It's another thing that a clinician has to do. (Learning session participant I-01)

1
2
3 Around a third (32.6%) of survey respondents questioned the reliability of the data collected,
4 indicating that they believed that it was 'vulnerable to "gaming" by organisations trying to look
5 good' and that the data was not comparable across organisations. One problem was that the NHS
6 Safety Thermometer asked data collectors to record whether the harm was 'old' or 'new' depending
7 on when it occurred. Staff reported that this was a problem because of the way the tool seemed to
8 obscure where and how the harm had occurred and opened up the possibility of blame.
9
10

11
12
13 *But because it went down on our record, it looked as though it was ours even though it goes*
14 *down as an old or a new, when you put those together it looks as though – oh look, they have*
15 *got pressure ulcers. (Learning session participant I-06)*
16
17

18 Substantial variability was evident in the extent to which organisations used the NHS Safety
19 Thermometer during Safety Express (Figs 1a and 1b). One region did not submit any data. In the first
20 month, only 12 acute organisations submitted data, making 712 patient-level entries. Rates of
21 organisational participation and data submission increased thereafter, with 140 organisations
22 submitting data at least once and an average of 60 organisations contributing data every month
23 throughout the collaborative. A total of 52,309 patient-level line entries were made during Safety
24 Express. A majority (71%) of monthly submissions contained at least 30 patients and 84% achieved
25 at least 20 patients. Data from hospital settings accounted for 90% of all data submitted, with the
26 remainder from non-acute settings including 3% from the patients' own home, 2% from nursing
27 homes and 5% from other settings. Within hospitals, 50% of the settings chosen by participants for
28 testing in hospitals were medical wards.
29
30
31
32
33
34
35

36 During the second, incentivised data collection phase of the programme, the number of
37 organisations contributing data increased dramatically: 719 organisations used the NHS Safety
38 Thermometer during 2012/13 (146 acute, 573 non-acute). This resulted in a large increase in patient
39 entries into the dataset: 1,882,558 patient entries (Fig. 1b). Diversity in the kinds of organisations
40 contributing data also increased during 2012-13, with particular growth in the proportion of patients
41 from non-acute settings. Of the non-acute, 136 were independent provider sites and 217 were
42 nursing homes. During this period, 58.3% of data were submitted from hospital settings, 7.8% from
43 the patients' own home, 2.3% from nursing homes and 31.6% from other settings.
44
45
46
47
48
49

50 **Programme Aim 3: Deliver improved outcomes**

51 The extent to which the programme met its aim of delivering improved outcomes was difficult to
52 assess, given variability in the number and consistency of organisations submitting data over time.
53 Control chart rules were used to interpret data on harm-free care over the two phases of the
54 programme both in the specific initial Safety Express subgroup of 12 organisations who were the
55
56
57
58
59
60

1
2
3 first to join (Fig 3a) and, separately, all organisations (including the initial Safety Express
4 subgroup)(Fig 3b).
5
6

7 The initial Safety Express subgroup organisations all reported data consistently over time. The
8 proportion of harm-free care reported by these organisations rose from 85.1% in January 2011 to
9 89.7% in April 2011 during Safety Express. This increased further to 91.4% by March 2012, and
10 remained stable up to March 2013 (throughout the incentivised data collection phase). (Fig 3a). The
11 proportion of patients who were deemed 'harm-free' in this subgroup did not reach the goal of 95%.
12
13

14 In all submitting trusts (including the initial Safety Express subgroup), the proportion of acute
15 patients reported as receiving harm-free care rose from 86.5% January 2011 to 90.2% by July 2011
16 during Safety Express. This increased further to 92.2% in July 2012, and stabilized thereafter, during
17 the incentivised data collection phase (end of March 2013) (Fig. 3b). Again, the 95% aspirational goal
18 was not achieved.
19
20
21
22
23

24 Discussion

25
26
27
28
29 This multi-method study of a large-scale, two-phase improvement programme using an innovative
30 approach to harm-free care adds to the growing body of evidence on large-scale programmes as a
31 means of securing change in healthcare. We set out to assess the extent to which the harm-free care
32 programme met its aims and the influences on the achievement of those aims. We found that the
33 programme struggled in developing a shared national, regional and locally aligned focus for the
34 harm-free care concept during Phase 1, with policy turbulence a major influence in frustrating goal
35 achievement. The goal of establishing a measurement system for harm-free care was achieved, but
36 in the face of considerable challenge. Whether the third and final goal of improved clinical outcomes
37 was achieved proved difficult to determine. These findings offer valuable learning about the design
38 and conduct of large-scale quality improvement programmes in healthcare. First, this study
39 illustrates the importance of significant upfront investment when launching new data collection
40 tools based on novel concepts, especially when such tools seek to standardise the measures used
41 across diverse settings. Second, it suggests that engagement in voluntary efforts such as quality
42 improvement collaboratives may be contingent on relatively stable organisational and broader
43 institutional contexts: participation and engagement in Safety Express remained patchy throughout
44 its history. It was not until broader structures had settled, and a financial incentive for data
45 collection was introduced in the second phase of the programme, that the reach and consistency of
46 data submission improved. Third, this study illustrates the challenges in interpreting evidence
47 relating to large-scale improvement. There is some indication that the proportion of patients
48 experiencing harm-free care increased over the both phases of the programme, but trends over time
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in the aggregate submissions must be interpreted cautiously since the same organisations did not
4 submit consistently over time nor did those who were submitting do so consistently, and case-mix
5 varied over time.
6
7

8
9 One potentially tempting conclusion from this study is that the first phase of the programme was
10 unnecessary since improved consistency of data submission did not occur until the second phase,
11 which financially incentivised data collection. This second phase also saw possible improvements in
12 clinical outcomes, even though little improvement support was available. Such a conclusion might
13 suggest that future efforts to secure improvement should focus primarily on financial incentives,
14 bypassing the messier and more uncertain path of voluntary, collaborative cooperation. But such an
15 argument neglects the important developmental role played by the first phase. Without this, the
16 second phase is might have foundered.
17
18
19
20
21

22 The developmental role of the first phase was especially critical in developing the NHS Safety
23 Thermometer. Though quality improvement projects are known to be prone to measurement and
24 data collection problems of various kinds, [31, 40, 41] the challenges in developing measures and
25 securing legitimacy are seldom reported. The concepts behind the NHS Safety Thermometer were
26 novel, emphasising a patient-centered approach that required rethinking of traditional metrics and
27 methods of data collection and display. Significant technical and social innovation was required to
28 maximise the chance that the data would be regarded as credible while minimising the risk that data
29 would be too irksome or burdensome to collect.[42] Despite the level of investment and testing,
30 some concerns about consistency, relevance and fairness endured among those submitting data, as
31 has been found elsewhere.[43]
32
33
34
35
36
37
38

39 The first phase of the programme may have been important in developing approaches, definitions
40 and tools, but less clear was the success of the collaborative model in securing change. Though the
41 harm-free care concept was broadly recognised by Safety Express participants as an original and
42 ingenious way to think about patient safety, none of the regions met the engagement metrics;
43 ability to engage was adversely affected by contextual influences, including massive system
44 instability that contributed to distraction, diminished energy, and voids of leadership.[44] It is also
45 likely that the number of participants was too low to achieve the necessary momentum in an area
46 the size of England. Further complicating engagement was the variation that existed between
47 regions and between organisations in their approach to implementation. Better understanding of
48 such variation might have enabled the national programme team to undertake a baseline
49 assessment and co-design a bespoke programme with each locality. These findings affirm earlier
50 evidence[14, 40, 45] indicating that quality improvement collaboratives may have some distinctive
51 strengths but are far from a straightforward solution. It adds to this evidence in demonstrating that
52
53
54
55
56
57
58
59
60

1
2
3 the potential of collaboratives may be heavily contingent on their political, economic and social
4 contexts. Simply put, though they may have advantages over more coercive methods for making
5 change,[46] their success is likely to depend on a supportive outer context. Better understanding of
6 how and when collaboratives are the right approach is an especially important goal given the known
7 risks and limitations associated other means of achieving change, including those associated with
8 use of financial incentives.[47]
9

10
11
12 A limitation of our study is that it was not possible to conduct a process evaluation of the
13 incentivised data collection phase. This means that it is not easy to identify the mechanisms that
14 might have contributed to the possible improvements in proportion of harm-free care that appear to
15 have coincided with the introduction of the data collection requirement. One possibility is that the
16 improvement observed was part of secular trend that was occurring anyway.[48] Another is that the
17 observed improvement is simply an artefact of the data collection process; as data collection
18 expanded, the case-mix became more diverse and included a higher proportion of patients at lower
19 risk of the four harms. A further possibility the introduction of financial incentives encouraged some
20 form of gaming,[49] though there is no direct evidence of this. Finally, it is possible that the observed
21 change was real: that clinical teams did use the NHS Safety Thermometer as intended, recognising
22 the value of a harm-free approach and using the data displays to identify where practice was falling
23 short and making changes. Such an interpretation is consistent with the general observation that
24 data plus feedback can act as an intervention, revealing unwarranted variations in practices, processes
25 and outcomes and helping to inform targets for improvement.[50, 51]
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40
41 Limitations of this study include its reliance on clinical outcome data reported to the programme by
42 the participating sites: the data were not independently collected, nor was it possible to engage in
43 verification or validation exercises. We interviewed all those who volunteered and sought
44 disconfirming evidence where possible, but it is possible that those interviewed were primarily
45 those with more positive views, since those participating in the collaborative were, almost by
46 definition, more engaged. The online survey did provide another opportunity to contribute, but it
47 was still vulnerable to capturing the views of the more engaged. It is not clear how generalizable the
48 findings will be to other contexts.
49
50
51
52

53
54 These findings offer important lessons for large-scale improvement programmes. They show that the
55 effort and time required to reach and implement an agreed approach to measurement for
56 improvement, particularly when the measures are novel, should not be underestimated.
57

58
59 Development of measurement systems requires both cultural change and technical leadership. It is
60 likely that at least six months is needed before an improvement programme starts to allow systems

1
2
3 to be optimised. Even then, contestation about data definitions and complaints about data
4 collection burden may persist and should be anticipated. The collaborative model may have rich
5 potential as a design and developmental phase in large-scale improvement programmes, but may
6 not on its own produce change when external contexts are unfavourable.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Competing interests:

MP, AH and AB were seconded to the Department of Health QIPP programme which ran the projects described in this manuscript. No other authors have a competing interest.

Funding:

The Department of Health Policy Research Programme (Reference No 0770017) funded the research programme of which this evaluation was a part. Analysis of data and write-up of this paper was supported by a Wellcome Trust Senior Investigator award (MDW) WT097899

Ethics committee approval:

NHS Research Ethics Committee approval was obtained for the process evaluation from the Leicestershire, Northamptonshire & Rutland Research Ethics Committee 1 (reference: 10/H0406/38). All personal identifiers have been removed.

Contributorship:

MDW and MP were involved in the study concept and design. SM, JM and PO collected and analysed the qualitative data. GJP, AH and MP analysed the quantitative data. MP, LB, GJP, AB and MDW were involved in the drafting and revised the manuscript. All the authors were involved in the critical revision of the final version of the manuscript.

Acknowledgements:

We thank all of the many organisations and individuals who participated in this research programme for their generosity and support, and our collaborators and the advisory group for the programme. Thanks to Dr Kevin Stewart, (Royal College of Physicians Clinical Effectiveness Unit, London UK) for his clinical leadership throughout the Safety Express programme and Kate Cheema at the South East Coast Quality Observatory for support with design of the NHS Safety thermometer, data collection and analysis. We thank Kasia Noone and Matt Cope for coordinating production of the manuscript.

Data Sharing Statement:

Additional unpublished data are not available.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Baseline assessment	Review 1	Review 2	Review 3	Final review
Safety Express Phase Reviews			Maintenance Phase Review	Incentivized Phase Review
Sept – Dec 2010	April 2011	Sept 2011	Sept 2012	March 2013
<ol style="list-style-type: none"> 1. A named individual in each region to link into the national team, appoint a local team and link into the QIPP team. 2. Identify areas of alignment and discourse between local, regional and national QIPP plans. 3. Recruit ten host organisations and ensure team composition included locality partners. 4. Identify regional faculty for a Safety Express improvement collaborative. 5. Field 100 people at learning session 1 of the collaborative. 	<ol style="list-style-type: none"> 1. Integration of the safe care plans into the regional QIPP plan. 2. Ten teams of ten participating in the collaborative. 3. Participation in fortnightly WebEx meetings (regional leaders) 4. Submission of monthly data using the NHS Safety Thermometer 5. Faculty support, (both 'national' and 'regional' – national included subject matter experts, i.e. in tissue viability / pressure ulcers and nutrition. Regional – leading clinicians and Q.I. experts) to teams between learning sessions (WebEx/site visits/phone calls). 	<ol style="list-style-type: none"> 1. Submission of five case studies of 'innovative practice' to the national team. 2. Submission of monthly data using the NHS Safety Thermometer from each organisation in the collaborative. 3. Well-defined plans for scale up to the remaining organisations in the region, including plans to work collaboratively with commissioners. 4. Identification of teams to put forward for national awards at a Summit event at the end of the pilot. 5. Plans to publish the work. 	<ol style="list-style-type: none"> 1. All organisations in the region to have participated in the CQUIN for collecting NHS ST data monthly. 2. Engagement with Clinical Commissioning Groups to raise awareness of 'harm-free' care programme and the NHS Safety Thermometer CQUIN (e.g. attendance at the Safe Care work stream meeting for commissioners, attendance at CQUIN master classes in which the details of the CQUIN were explained to commissioners from each region). 3. Review regional level data. 4. Publication of the results of the QIPP Safe Care programme of work. 5. Evidence of regional planning for delivery of improvement for the 2013/14 CQUIN. 	<ol style="list-style-type: none"> 1. All organisations participating in the 2013/14 CQUIN to aim to achieve 50% improvement in reduction of the four harms by March 2014. 2. Evidence of the harm-free care programme in Trust's Quality Accounts and/or Trust Board reports. 3. All CCGs commissioning harm-free care locally. 4. All CCGs and organisations to have systems in place to embed 'harm-free' care into contracts and to embed into the new NHS and social care structures. 5. Evidence of support to assist organisations who have not achieved 50% improvement.

1
2
3
4
5 **Table 1:** Safety Express key deliverables and review points for regions, determined in advance
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

<i>Site characteristic</i>	<i>Descriptor</i>	<i>Survey respondents*</i>
Organisation (n=133)	Acute trust	63.9%
	Community trust	24.1%
	Mental health trust	2.3%
	Primary care trust	7.5%
	Strategic Health Authority	6.0%
	Other	4.6%
Staff level banding** (n=134)	Bands 1-4	0.7%
	Bands 5-6	10.4%
	Bands 7-8	61.9%
	Above Band 8	28.4%
	Other	2.1%
Regional cluster (n=134)	North	26.9%
	Midlands/East of England	26.9%
	London	6.7%
	South East Coast	9.7%
	South Central	21.6%
	South West	6.0%
	Prefer not to say	6.0%

Table 2: Survey respondent characteristics

*Some respondents chose more than one option to describe their organisation, banding, and region.

** Most jobs in the NHS are covered by the Agenda for Change (AfC) pay scales. This covers all staff except doctors, dentists and the most senior managers. The AfC job evaluation system determines a point score which is used to match jobs to one of the nine pay bands and determine levels of basic salary (ref: <http://www.nhscareers.nhs.uk/explore-by-career/nursing/pay-for-nurses/>.)

Region	Population ¹ (millions)	Budget ² (in billions)	Collaborative participation			Alignment with workstream goals ⁴					
			Number of host organisations ³ participating in Safety Express	LS1 ⁴ Attendees	LS2 Attendees	LS3 Attendees	Baseline Assessment	Review 1	Review 2	Review 3	Final Review
				(Jan 11)	(Mar 11)	(Jun 11)	(Sep - Dec 10)	(April 11)	(Sep 11)	(Sep 12)	(Mar 13)
1	6.7	£12	15	112	85	72	Amber	Red	Red	Amber	Amber
2	2.5	£4.7	6	31	24	19	Red	Red	Red	Red	Red
3	4.9	£9.3	5	27	25	7	Red	Red	Red	Red	Red
4	4.1	£7.7	10	39	55	32	Amber	Amber	Amber	Red	Red
5	5.3	£5.2	9	87	45	18	Amber	Amber	Red	Red	Red
6	5.4	£10.1	9	22	28	31	Amber	Amber	Green	Green	Green
7	7.4	£13.9	10	75	59	60	Red	Red	Green	Green	Amber
8	4.1	£7.7	22	70	53	43	Amber	Amber	Amber	Amber	Red
9	3.9	£7.3	11	31	22	48	Red	Amber	Red	Red	Red
10	4.9	£9.3	31	81	77	118	Red	Red	Red	Red	Amber

Table 3: Regions’ participation in the collaborative and alignment with programme goals

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

¹ Population in millions rounded to one decimal place; ² Allocation of spend to the nearest £100,000 to each SHA region in FY 2010/11; ³ A host organisation was defined as the lead organisation who collaborated with other organisations across the health economy. ⁴ LS = learning session

For peer review only

1 References

- 1 Landrigan CP, Parry GJ, Bones CB, et al. Temporal trends in rates of patient harm resulting from medical care, *N Engl J Med* 2010;363:2124-34.
- 2 Provenzano A, Rohan S, Trevejo E, et al. Evaluating inpatient mortality: a new electronic review process that gathers information from front-line providers, *BMJ Qual Saf* 2015;24:31-7.
- 3 Hogan H, Healey F, Neale G, et al. Preventable deaths due to problems in care in English acute hospitals: a retrospective case record review study, *BMJ Qual Saf* 2012;21:737-45.
- 4 Berwick DM, Calkins DR, Joseph McCannon C, et al. The 100 000 lives campaign: Setting a goal and a deadline for improving health care quality, *J Am Med Assoc* 2006;295:324-7.
- 5 Benning A, Ghaleb M, Suokas A, et al. Large scale organisational intervention to improve patient safety in four UK hospitals: mixed method evaluation, *BMJ* 2011;342:d195 doi:10.1136/bmj.d195 [published Online First: Feb 3].
- 6 Benning A, Dixon-Woods M, Nwulu U, et al. Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase, *BMJ* 2011;342:d195-.
- 7 Krumholz HM, Bradley EH, Nallamothu BK, et al. A Campaign to Improve the Timeliness of Primary Percutaneous Coronary Intervention: Door-to-Balloon: An Alliance for Quality, *J Am Coll Cardiol Intv* 2008;1:97-104.
- 8 Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study, *The Lancet infectious diseases* 2012.
- 9 Bion J, Richardson A, Hibbert P, et al. 'Matching Michigan': a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England, *BMJ Qual Saf* 2012.
- 10 Forster AJ, Worthington JR, Hawken S, et al. Using prospective clinical surveillance to identify adverse events in hospital, *BMJ Quality & Safety* 2011;20:756-63.
- 11 Morris-Thompson T, Aldred V, Clark N, et al. Safety Express: a strategic health authority's approach, *British journal of nursing* 2012;21:677-83.
- 12 Lecko C. Patient safety and nutrition and hydration in the elderly. 2013.
- 13 Health and Social Care Information Centre. NHS Safety Thermometer. 2013;2016.

- 1
2
3 14 Hulscher ME, Schouten LM, Grol RP, et al. Determinants of success of quality improvement
4 collaboratives: what does the literature show? *BMJ Quality & Safety* 2012.
5
6
7 15 Dixon-Woods M, Bosk CL, Aveling EL, et al. Explaining Michigan: developing an ex post theory of a
8 quality improvement program, *Milbank Q* 2011;89:167-205.
9
10 16 Institute for Healthcare Improvement. The Breakthrough Series: IHI's Collaborative Model for
11 Achieving Breakthrough Improvement. IHI Innovation Series white paper. *Boston: Institute for*
12 *Healthcare Improvement* 2003.
13
14 17 Ozieranski P, Robins V, Minion J, et al. Running a hospital patient safety campaign: a qualitative
15 study, *Journal of Health Organization and Management* 2014;28:562-75.
16
17
18 18 Pronovost PJ, Goeschel CA, Marsteller JA, et al. Framework for patient safety research and
19 improvement, *Circulation* 2009;119:330-7.
20
21
22 19 Dixon-Woods M, McNicol S, Martin GP. Ten challenges in improving quality in health care: lessons
23 from the Health Foundation's programme evaluations and relevant literature, *BMJ Quality & Safety*
24 2012;21:876-84.
25
26
27 20 Aveling EL, Martin G, Armstrong N, et al. Quality improvement through clinical communities:
28 eight lessons for practice, *J of Health Org and Mgt* 2012;26:158-74.
29
30
31 21 Soo S, Berta W, Baker GR. Role of champions in the implementation of patient safety practice
32 change, *Healthc Q* 2009;12:123-8.
33
34
35 22 Fuller C, Michie S, Savage J, et al. The Feedback Intervention Trial (FIT) - Improving Hand-Hygiene
36 Compliance in UK Healthcare Workers: A Stepped Wedge Cluster Randomised Controlled Trial, *PLoS*
37 *ONE* 2012;7.
38
39
40 23 Dixon-Woods M, McNicol S, Martin G. Ten challenges in improving quality in healthcare: lessons
41 from the Health Foundation's programme evaluations and relevant literature, *BMJ Quality Safety*
42 2012;21:876-84.
43
44
45 24 Cronshaw HL, Daniels R, Bleetman A, et al. Impact of the Surviving Sepsis Campaign on the
46 recognition and management of severe sepsis in the emergency department: are we failing? *Emerg*
47 *Med J* 2011;28:670-5.
48
49
50 25 Power M, Tyrrell PJ, Rudd AG, et al. Did a quality improvement collaborative make stroke care
51 better? A cluster randomized trial, *Implementation Science* 2014;9:40-.
52
53
54 26 Hawe P. Lessons from complex interventions to improve health, *Annu Rev Public Health*
55 2015;36:307-23.
56
57
58 27 Dixon-Woods M. The problem of context in quality improvement. 2014.
59
60

- 1
2
3 28 Datta J, Petticrew M. Challenges to evaluating complex interventions: a content analysis of
4 published papers, *BMC Public Health* 2013;13:1.
5
6
7 29 Pronovost PJ, Lilford R. Analysis & commentary: A road map for improving the performance of
8 performance measures, *Health Aff (Millwood)* 2011;30:569-73.
9
10 30 Marshall M, Pronovost P, Dixon-Woods M. Promotion of improvement as a science, *Lancet*
11 2013;381:419-21.
12
13
14 31 Benn J, Burnett S, Parand A, et al. Studying large-scale programmes to improve patient safety in
15 whole care systems: Challenges for research, *Soc Sci Med* 2009;69:1767-76.
16
17
18 32 Portela MC, Pronovost PJ, Woodcock T, et al. How to study improvement interventions: a brief
19 overview of possible study types, *BMJ Qual Saf* 2015;24:325-36.
20
21
22 33 Dixon-Woods M, Baker M, Charles J, et al. Culture and behaviour in the English National Health
23 Services: overview of lessons from a large multi-method study, *BMJ Qual Saf* 2013;23:106-15.
24
25 34 Creswell, John W., Plano Clark, Vicki L., Designing and conducting mixed methods research. Los
26 Angeles: SAGE Publications 2011.
27
28 35 Dixon-Woods M, Agarwal S, Jones D, et al. Synthesising qualitative and quantitative evidence: A
29 review of possible methods, *Journal of Health Services Research and Policy* 2005;10:45-53.
30
31
32 36 Charmaz K. Constructing grounded theory: A practical guide through qualitative analysis. London:
33 Sage 2006.
34
35 37 Glaser B, Strauss A. The discovery of grounded theory. Hawthorne, NY: Aldine Publishing
36 Company 1967.
37
38
39 38 Altheide DL. Ethnographic content analysis. In: Lewis Beck MS, Bryman A, Liao TF, eds. The Sage
40 Encyclopaedia of Social Science Research Methods. Thousand Oaks, Ca: Sage 2004.
41
42
43 39 Power M, Fogarty M, Madsen J, et al. Learning from the design and development of the NHS
44 Safety Thermometer, *Int J Qual Health Care* 2014;26:287-97.
45
46
47 40 Schouten LM, Hulscher ME, van Everdingen JJ, et al. Evidence for the impact of quality
48 improvement collaboratives: systematic review, *BMJ* 2008;336:1491-4.
49
50
51 41 Needham DM, Sinopoli DJ, Dinglas VD, et al. Improving data quality control in quality
52 improvement projects, *Int J Qual Health Care* 2009;21:145-50.
53
54
55 42 Pronovost PJ, Nolan T, Zeger S, et al. How can clinicians measure safety and quality in acute care?
56 *Lancet* 2004;363:1061-7.
57
58
59
60

1
2
3 43 Dixon-Woods M, Leslie M, Tarrant C, et al. Explaining Matching Michigan: an ethnographic study
4 of a patient safety program, *Implement Sci* 2013;8:70.

5
6
7 44 McKee L, Charles K, Dixon-Woods M, et al. New” and distributed leadership in quality and safety
8 in healthcare, or “old” and hierarchical? An interview study with strategic stakeholders *Journal of*
9 *Health Services Research and Policy* 2013;DOI: 10.1177/1355819613484460.

10
11
12 45 Øvretveit J, Bate P, Cleary P, et al. Quality collaboratives: lessons from research, *Quality and*
13 *safety in health care* 2002;11:345-51.

14
15
16 46 Martin G, Armstrong N, Dixon-Woods M, et al. Professionalism Redundant, Reshaped, or
17 Reinvigorated? Realizing the ‘Third Logic’ in Contemporary Healthcare, *Journal of Health and Social*
18 *Behaviour* 2015;Published online before print.

19
20
21 47 Roland M, Dudley RA. How Financial and Reputational Incentives Can Be Used to Improve
22 Medical Care, *Health Serv Res* 2015;50:2090-115.

23
24
25 48 Chen YF, Hemming K, Stevens AJ, et al. Secular trends and evaluation of complex interventions:
26 the rising tide phenomenon, *BMJ Qual Saf* 2016;25:303-10.

27
28
29 49 Bevan G, Hood C. What's measured is what matters: Targets and gaming in the English public
30 health care system, *Public Administration* 2006;84:517-38.

31
32
33 50 Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and
34 healthcare outcomes. *Cochrane database of systematic reviews (Online)* 2012;6.

35
36
37 51 Brown JR, Solomon RJ, Sarnak MJ, et al. Reducing Contrast-Induced Acute Kidney Injury Using a
38 Regional Multicenter Quality Improvement Intervention. *Circulation: Cardiovascular Quality and*
39 *Outcomes* 2014.




Figure 1a: Number of organisations submitting data over time*
 *NHS Trusts submitting NHS Safety Thermometer data over time, from the start of the Safety Express programme ('Phase 1') through to end of the first period of incentivised data collection ('Phase 2'). Bar height represents the total unique NHS Trusts submitting within the month. In January 2011, 12 organisations submitted. In March 2013, this had risen to 252 organisations.

1a
 73x50mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1b: Number of patient entries submitted over time.*

*Number of individual patient-level entries submitted to the NHS Safety Thermometer over time from the start of the Safety Express programme ('Phase 1') through to end of the first period of incentivised data collection ('Phase 2'). Bar height represents the total patients submitted within the month. In January 2011, 712 patients were surveyed and their data submitted against the 'harm-free' Care measure. In March 2013, this was 98,372 patients.

1b
70x49mm (300 x 300 DPI)




Figure 2: Timeline of key political and policy events 2009-2012

Fig. 2
77x51mm (300 x 300 DPI)




Figure 3a: Percent harm-free care over time for patient entries submitted from the initial Safety Express ('Phase 1') cohort in January 2011 over time, until the end of the incentivised data collection period ('Phase 2') plotted as a P prime chart*

*P' Chart showing percent of patients from the initial cohort of Safety Express ('Phase 1') organisations experiencing harm-free care as defined by the NHS Safety Thermometer, presented over time. These data are plotted as a P prime (P') chart; a type of control chart used for time-series data with a large denominator. Individual data points represent the % of patients in the cohort who received harm-free care each month; in January 2011 this was 85.1%. In March 2013, this was 91.4%. Control limits are used to apply control chart rules to detect special cause. The original plot of these data highlighted three distinct phases, indicated by the readjusted mean line.

3a
60x33mm (300 x 300 DPI)




Figure 3b: Percent harm-free care over time for patient entries from all submitting acute care trusts over time, from the beginning of the 'Safety Express' period ('Phase 1') to the end of the incentivised data collection period ('Phase 2') plotted as a P prime chart*

*P' Chart showing percent of patients experiencing harm-free care (as defined by the NHS Safety Thermometer) whilst an inpatient in an acute bed, at any submitting NHS Trust, presented over time. Similar to Figure 3a, these data are plotted as a P prime (P') chart. Individual data points represent the % of patients who received harm-free care each month; in January 2011 this was 86.5%. In March 2013, this was 92.2%. Control limits are used to apply control chart rules to detect special cause. The original plot of these data highlighted three distinct phases, indicated by the readjusted mean line.

3b
60x33mm (300 x 300 DPI)